<!DOCTYPE html>
<html lang="en">
<head>
    <meta charset="utf-8">
    <meta http-equiv="X-UA-Compatible" content="IE=edge">
    <meta content="width=device-width, initial-scale=1, maximum-scale=1, user-scalable=no" name="viewport">
    <meta name="description" content="نظام معلومات الأدوية السعودي Saudi Drugs Information System">
    <meta name="author" content="Saudi Food & Drug Authority (SFDA)">
    <noscript><meta http-equiv="refresh" content="0; url=/noScript.html" /></noscript>
    <link rel="shortcut icon" href="/favicon.ico">
    <title>&#x646;&#x638;&#x627;&#x645; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</title>
    <link href="/fonts/roboto/roboto.css?v=53F8z0aw8DRnG9ou9x1tuKMPbNjRZWM-VBHl3B0s9-o" rel="stylesheet" />
    <link href="/fonts/material-icons/materialicons.css?v=8pEJ8MWsFzHRDLY0NI5rssf6T6vankxrJDPnnZxOGrg" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-rtl.css?v=0env-Atj9mTPLILmJGwuDlLIOS_Akxxy4gnH1UUtrjU" rel="stylesheet" />
    <link href="/lib/bootstrap/dist/css/bootstrap-glyphicons.css?v=U5a39oen_WYzVAAexH5aoahbpqlKHcIzQrnXujf1yio" rel="stylesheet" />
    <link href="/lib/bootstrap-select/dist/css/bootstrap-select.css?v=DeY2lH0e0tmNnO9XZ-gGVOGk6_YoWlZ49y7CnD3ST00" rel="stylesheet" />
    <link href="/lib/toastr/toastr.css?v=kKePN_CyxTiMEgsSDu_7z21ru07YOZtR-0UV0JOkt5o" rel="stylesheet" />
    <link href="/lib/famfamfam-flags/dist/sprite/famfamfam-flags.css?v=JVJiF3s2_kk99xQHfYhfxo_-Dd52ZIruDMOILwPkqv0" rel="stylesheet" />
    <link href="/lib/font-awesome/css/font-awesome.css?v=YIHlqxkiJtENTMuzIHC9EfZaB5RniGr7kF7juUQJUuc" rel="stylesheet" />
    <link href="/lib/Waves/dist/waves.css?v=nd3hxjNg6DhkuFIz5IbxLK8Xw2ac0blsDQpF4pkJxUc" rel="stylesheet" />
    <link href="/lib/animate.css/animate.css?v=IT6GQizZpVcaM1_L_mIiNAYVvZErMgfwewf1GGWXG_I" rel="stylesheet" />
    <link href="/css/materialize.css?v=ey-J3xahkqficOYUHVX3jexmzvRFrge9bmux4CQr1DQ" rel="stylesheet" />
    <link href="/css/Publicstyle.css?v=xhOiVjq-54ODzSIeHXoascHsEJm_n_bIHqZatpxnYhg" rel="stylesheet">
    <link href="/css/Comman.css?v=bcS6_IRqBsBcY1mS_iriWWanrYR0Scdo1ffk8rQGXwQ" rel="stylesheet" />
    <link href="/css/themes/all-themes.css?v=eGSl5zNTWrXYfUx_EJW9ksC3CUTUUxvxmPiA3aQDtQo" rel="stylesheet" />
    <link href="/view-resources/Views/Shared/_Layout.css?v=BLxBuNISlF2O5EBHWdsX039NvnIHy-GtcqeI_MbyIc0" rel="stylesheet" />
    <link href="/lib/enjoyhint/enjoyhint.css?v=rSxIyBbiAvx_48ZcFxbn2DNPCCgEc0FXa2Vb72enxk4" rel="stylesheet" />
    <link href="/lib/dropzone/dropzone.css?v=IQDlHJdeYZ4gMH87EuB1yEG7ujA7DSEkV_SWfACk8Rg" rel="stylesheet" />

    <!-- View specific styles -->
    
    <script type="text/javascript" nonce="c7f26c8w">
        // This is used to get the application's root path from javascript. It's useful if you're running application in a virtual directory under IIS.
        var abp = abp || {};
        abp.appPath = '/';

    </script>
    <style>
        .popover .popover-title {
            text-align: right;
            font-weight: bold;
        }
        .popover .popover-content {
            text-align: right;
            font-size: 14px;
            font-family: 'Almarai', sans-serif;
            color: black;
        }
       
    </style>
</head>
<body>
    <!-- Page Loader -->
    <div class="page-loader-wrapper">
        <div class="loader">
            <div class="preloader">
                <div class="spinner-layer pl-blue">
                    <div class="circle-clipper left">
                        <div class="circle"></div>
                    </div>
                    <div class="circle-clipper right">
                        <div class="circle"></div>
                    </div>
                </div>
            </div>
            <p>&#x628;&#x631;&#x62C;&#x627;&#x621; &#x627;&#x644;&#x625;&#x646;&#x62A;&#x638;&#x627;&#x631; ...</p>
        </div>
    </div>
    <!-- #END# Page Loader -->
    <!-- Overlay For Sidebars -->
    <div class="overlay"></div>
    <!-- #END# Overlay For Sidebars -->
    <!-- Search Bar -->
    <!-- Top Bar -->
    <nav class="navbar navbar-inverse naav" style="margin-bottom: 0;">
        <div class="container-fluid">
            <div class="navbar-header">
                <button type="button" class="navbar-toggle" data-toggle="collapse" data-target="#myNavbar">
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                    <span class="icon-bar"></span>
                </button>
            </div>
            <div class="collapse navbar-collapse rtl" id="navbar-collapse">
                <ul class="nav navbar-nav navbar-right">
                    <li><a href="/home/DrugSearch">&#x627;&#x644;&#x623;&#x62F;&#x648;&#x64A;&#x629;</a></li>
                        <li><a href="/Account/Login"><i class="fa fa-key"></i>&nbsp;&#x62A;&#x633;&#x62C;&#x64A;&#x644; &#x627;&#x644;&#x62F;&#x62E;&#x648;&#x644;</a></li>
                </ul>
                <ul class="nav navbar-nav navbar-left">
                    <li class="dropdown">
    <a href="javascript:void(0);" class="dropdown-toggle" data-toggle="dropdown" role="button">
        <i class="famfamfam-flags sa" title="&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;"></i>
        <span>&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</span>
        <b class="caret"></b>
    </a>
    <ul class="dropdown-menu pull-right">
                <li><a href="/AbpLocalization/ChangeCulture?cultureName=en"><i class="famfamfam-flags gb"></i> English</a></li>

    </ul>
</li>

                </ul>
            </div>
        </div>
    </nav>
    <section id="mainContent" class="content">
        <nav class="navbar naav" style="margin-bottom: 0;">
            <div class="container-fluid">
                <ul class="nav navbar-nav">
                    <li>
                        <a class="text-center" href="/">
                            <img src="/images/logo_sdi.png" style="margin: auto;" width="250">
                        </a>
                    </li>
                </ul>
                <div class="navbar-header navbar-toggle2 ">
                    <button type="button" class="navbar-toggle navbar-toggle2" data-toggle="collapse"
                            data-target="#myNavbar2">
                        <span class="icon-bar icon-bar2 "></span>
                        <span class="icon-bar icon-bar2"></span>
                        <span class="icon-bar icon-bar2"></span>
                    </button>
                </div>
                <div class="collapse navbar-collapse " id="myNavbar2">
                    <ul class="nav navbar-nav">
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover" data-placement="bottom" title="" data-content="موقع الكترونى يمكن شركات ووكلاء الادويه من رفع النشرات الممارس الصحى ونشرة معلومات المريض وصورة عبوة الدواء المعتمدة من الهيئة العامة للعذاء والدواء بهدف بناء مرجع وطنى للادوية المسجلة يمكن الرجوع له من قبل الممارس الصحى والمريض كمصدر موثوق للمعلومات الدوائية"
                               data-original-title="&#x645;&#x646; &#x646;&#x62D;&#x646;">
                                &#x645;&#x646; &#x646;&#x62D;&#x646;
                            </a>
                        </li>
                        <li>
                            <a href="#" class="text-right waves-effect" data-trigger="focus"
                               style="color: #4276a1;" data-container="body" data-toggle="popover"
                               data-placement="bottom"
                               title=""
                               data-content="&#x627;&#x630;&#x627; &#x643;&#x627;&#x646; &#x644;&#x62F;&#x64A;&#x643;&#x645; &#x645;&#x644;&#x627;&#x62D;&#x638;&#x627;&#x62A; &#x627;&#x648; &#x627;&#x642;&#x62A;&#x631;&#x627;&#x62D;&#x627;&#x62A; &#x64A;&#x631;&#x62C;&#x649; &#x627;&#x644;&#x62A;&#x648;&#x627;&#x635;&#x644; &#x639;&#x644;&#x649;   SDI@SFDA.GOV.SA"
                               data-original-title="&#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;">
                                &#x62A;&#x648;&#x627;&#x635;&#x644; &#x645;&#x639;&#x646;&#x627;
                            </a>
                        </li>

                    </ul>
                </div>
            </div>
        </nav>
        

<div class="col-xs-12">
    <div class="row text-center">
        <a href="/" class="btn bg-blue btn-lg m-b-10 hover-white">&#x628;&#x62D;&#x62B; &#x62C;&#x62F;&#x64A;&#x62F;</a>
    </div>
</div>
<div class="jumbotron" style="margin-bottom: 0px; background-color: white !important;">
    <h3 class="text-center" style="color: #57aabf; ">Search Results</h3>
    <hr width="20%" style="border-top: 3px solid #54ae90;">

    <br>
    <table class="table s-row">
        <thead style="margin-bottom: 30px !important">
                <tr>
                    <th id="M" style="color:white;">
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x627;&#x644;&#x645;&#x645;&#x627;&#x631;&#x633; &#x627;&#x644;&#x635;&#x62D;&#x64A;</a>
                    </th>
                    <th id="A" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x639;&#x631;&#x628;&#x64A;&#x629;</a>
                    </th>
                    <th id="E" style="color:white;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x646;&#x634;&#x631;&#x629; &#x645;&#x639;&#x644;&#x648;&#x645;&#x627;&#x62A; &#x627;&#x644;&#x645;&#x631;&#x64A;&#x636; &#x628;&#x627;&#x644;&#x627;&#x646;&#x62C;&#x644;&#x64A;&#x632;&#x64A;&#x629;</a>
                    </th>
                    <th id="f" class="active-tab" type='button'>
                        <a href="javascript:void(0)" style="color: white;">&#x635;&#x648;&#x631; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>
                    <th id="D" style="color:white; background-color: #47a4ba;" type='button'>
                        <a href="javascript:void(0)"
                           style="color: white;">&#x628;&#x64A;&#x627;&#x646;&#x627;&#x62A; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</a>
                    </th>

                </tr>
        </thead>
    </table>
    <div id="D-div" class="box-data" style="display: block;">
        <div class="row">

<div class="modal-body rtl">
    <div class="tab-content">
        <div role="tabpanel" class="tab-pane m-r-60  animated fadeIn active" id="edit-user-details">
<div class="row clearfix">
                    <div class="col-lg-6 col-md-6 col-sm-6">
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="RegisterNumber">&#x631;&#x642;&#x645; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        106-10-13
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="RegisterYear">&#x633;&#x646;&#x629; &#x627;&#x644;&#x62A;&#x633;&#x62C;&#x64A;&#x644;</label>
                                    <div class="form-line">
                                        2013
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="TradeName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x62A;&#x62C;&#x627;&#x631;&#x64A;</label>
                                    <div class="form-line">
                                        ANDROCUR 50MG TAB
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label col-view" for="ScientificName">&#x627;&#x644;&#x627;&#x633;&#x645; &#x627;&#x644;&#x639;&#x644;&#x645;&#x64A;</label>
                                    <div class="form-line">
                                        CYPROTERONE ACETATE
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label " for="Strength">&#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        50
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="StrengthUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62A;&#x631;&#x643;&#x64A;&#x632;</label>
                                    <div class="form-line">
                                        mg
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="AdministrationRouteName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x625;&#x633;&#x62A;&#x639;&#x645;&#x627;&#x644;</label>
                                    <div class="form-line">
                                        Oral use
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PharmaceuticalFormName">&#x627;&#x644;&#x634;&#x643;&#x644; &#x627;&#x644;&#x635;&#x64A;&#x62F;&#x644;&#x627;&#x646;&#x64A;</label>
                                    <div class="form-line">
                                        Tablet
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Size">&#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="SizeUnitName">&#x648;&#x62D;&#x62F;&#x629; &#x627;&#x644;&#x62D;&#x62C;&#x645;</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageSize">&#x62D;&#x62C;&#x645; &#x627;&#x644;&#x639;&#x628;&#x648;&#x629;</label>
                                    <div class="form-line">
                                        20
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="PackageTypeName">&#x627;&#x646;&#x648;&#x627;&#x639; &#x627;&#x644;&#x639;&#x628;&#x648;&#x627;&#x62A;</label>
                                    <div class="form-line">
                                        Blister
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="LegalStatusName">&#x637;&#x631;&#x64A;&#x642;&#x629; &#x627;&#x644;&#x635;&#x631;&#x641;</label>
                                    <div class="form-line">
                                        Prescription
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6">
                                <div class="form-group">
                                    <label class="form-label" for="ProductControlName">&#x62D;&#x627;&#x644;&#x629; &#x627;&#x644;&#x645;&#x631;&#x627;&#x642;&#x628;&#x629;</label>
                                    <div class="form-line">
                                        Uncontrolled
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="DrugTypeName">&#x646;&#x648;&#x639; &#x627;&#x644;&#x62F;&#x648;&#x627;&#x621;</label>
                                    <div class="form-line">
                                        NCE
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="ShelfLife">&#x645;&#x62F;&#x629; &#x627;&#x644;&#x635;&#x644;&#x627;&#x62D;&#x64A;&#x629; &#x628;&#x627;&#x644;&#x623;&#x634;&#x647;&#x631;</label>
                                    <div class="form-line">
                                        48
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="StorageConditionsName">&#x634;&#x631;&#x648;&#x637; &#x627;&#x644;&#x62A;&#x62E;&#x632;&#x64A;&#x646;</label>
                                    <div class="form-line">
                                        store below 25°c
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="Price">&#x633;&#x639;&#x631; &#x627;&#x644;&#x62C;&#x645;&#x647;&#x648;&#x631; &#x628;&#x627;&#x644;&#x631;&#x64A;&#x627;&#x644;  ( &#x627;&#x644;&#x633;&#x639;&#x631; )</label>
                                    <div class="form-line">
                                        63.55
                                    </div>
                                </div>
                            </div>
                        </div>
                        <div class="row clearfix">
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Manufacture_NameEn" name="Manufacture.NameEn" value="BAYER WEIMAR GmbH UND CO. KG" />
                                        <label class="form-label" for="Manufacture_NameEn">&#x627;&#x644;&#x645;&#x635;&#x646;&#x639;</label>
                                        <div class="form-line">
                                            BAYER WEIMAR GmbH UND CO. KG
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <input type="hidden" id="Agent" name="Agent" value="[Agent 392]" />
                                        <label class="form-label">&#x627;&#x644;&#x648;&#x643;&#x64A;&#x644;</label>
                                        <div class="form-line">
                                            AL-KAMAL IMPORT OFFICE CO. LTD.
                                        </div>
                                    </div>
                                </div>
                                <div class="col-sm-6 col-lg-6">
                                    <div class="form-group">
                                        <label class="form-label" for="Company_NameEn">&#x627;&#x644;&#x634;&#x631;&#x643;&#x629; &#x627;&#x644;&#x645;&#x633;&#x648;&#x642;&#x629;</label>
                                        <div class="form-line">
                                            BAYER PHARMA AG
                                        </div>
                                    </div>
                                </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode1">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 1</label>
                                    <div class="form-line">
                                        G03HA01
                                    </div>
                                </div>
                            </div>
                            <div class="col-sm-6 col-lg-6">
                                <div class="form-group">
                                    <label class="form-label" for="AtcCode2">&#x643;&#x648;&#x62F; &#x627;&#x644;&#x643;&#x64A;&#x645;&#x64A;&#x627;&#x621; &#x627;&#x644;&#x639;&#x644;&#x627;&#x62C;&#x64A;&#x629; &#x627;&#x644;&#x62A;&#x634;&#x631;&#x64A;&#x62D;&#x64A;&#x629; 2</label>
                                    <div class="form-line">
                                        
                                    </div>
                                </div>
                            </div>
                        </div>
                    </div>
                </div>
        </div>
    </div>
</div>

        </div>
    </div>
    <div id="E-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> SFDA PIL</span>
                <span style="font-size:small;">  (Patient Information Leaflet (PIL) are under review by Saudi Food and Drug Authority)</span>

            </div>
</div>


<div class="clearfix ltr">
    <div class="col-lg-12 col-md-12 col-sm-12 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="InventedNameEn">1. What this product is and what it is used for</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Androcur is a hormone preparation acting against male sex hormones<br />(androgens). The active substance is cyproterone acetate.<br />Androcur reduces the testosterone (an androgen) concentration in the blood.<br />This in turn leads to a reduction of sex drive.<br />Androgens encourage the growth of prostate cancer. In these patients,<br />Androcur inhibits this effect.<br />Androcur is used for<br />&nbsp;reduction of sex drive in cases of sexual deviations in men<br />&nbsp;antiandrogen treatment in inoperable prostate cancer</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="form-group clearfix">
            <label style="float: left" class="h2" for="PrecautionsEn">2. What you need to know before you use this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Do not take Androcur<br />Do not take Androcur if you have any of the conditions listed below. If any of<br />these apply to you, tell your doctor before starting to take Androcur.<br />When prescribed for reduction of sex drive in cases of sexual deviations in<br />men<br />&nbsp;if you have a liver disease<br />&nbsp;if you suffer from hereditary disturbances of liver function with impaired<br />excretion of the red blood cell pigment called bilirubin (Dubin-Johnson<br />Syndrome or Rotor-Syndrome)<br />&nbsp;if you have or ever had a benign or malignant liver tumor<br />&nbsp;if you have or ever had a benign brain tumor (meningioma)<br />&nbsp;if you have a wasting disease (a disease causing decay or loss of strength)<br />&nbsp;if you suffer from severe chronic depression<br />&nbsp;if you have or ever had a disorder affecting the blood circulation: in<br />particular, those conditions relating to thrombosis (the formation of a<br />blood clot) in the blood vessels (thromboembolic process)<br />&nbsp;if you have severe diabetes mellitus with blood vessel changes<br />&nbsp;if you have sickle cell anemia<br />&nbsp;if you are allergic (hypersensitive) to cyproterone acetate or any of the<br />other ingredients of Androcur<br />When prescribed for antiandrogen treatment in inoperable prostate cancer<br />&nbsp;if you have a liver disease<br />&nbsp;if you suffer from hereditary disturbances of liver function with impaired<br />excretion of the red blood cell pigment called bilirubin (Dubin-Johnson<br />Syndrome or Rotor-Syndrome)<br />&nbsp;if you have or ever had a benign or malignant liver tumor (only if these are<br />not due to metastases from carcinoma of the prostate)<br />&nbsp;if you have or ever had a benign brain tumor (meningioma)<br />&nbsp;if you have a wasting disease (a disease causing decay or loss of strength,<br />with the exception of inoperable carcinoma of the prostate)<br />&nbsp;if you suffer from severe chronic depression<br />&nbsp;if you have a disorder affecting the blood circulation: in particular, those<br />conditions relating to thrombosis (the formation of a blood clot) in the<br />blood vessels (thromboembolic process)<br />&nbsp;if you are allergic (hypersensitive) to cyproterone acetate or any of the<br />other ingredients of Androcur<br />Warnings and precautions<br />Tell your doctor if you suffer from diabetes, since he/she may need to<br />adjust your antidiabetic medication. This requires strict supervision during<br />treatment with Androcur (see also section &lsquo;Do not take Androcur&rsquo;).<br />Anemia has been reported during treatment with Androcur. Therefore, your<br />doctor will monitor your red-blood cell count during treatment.<br />Data from animal studies suggest that high doses of Androcur may decrease<br />the function of the hormone-producing gland attached to the kidneys<br />(adrenal glands). Therefore your doctor may conduct some tests to monitor<br />this effect during treatment with Androcur.<br />Use of cyproterone acetate has been linked to the development of a<br />generally benign brain tumour (meningioma). The risk increases especially<br />when you use it for longer duration (several years) or for a shorter duration<br />with high doses (25 mg per day and above). If you notice any symptoms<br />such as changes in vision (e.g. seeing double or blurriness), hearing loss or<br />ringing in the ears, loss of smell, headaches that worsen with time, memory<br />loss, seizures, weakness in your arms or legs, you must tell your doctor<br />straightaway. If you are diagnosed with meningioma, your doctor will stop<br />your treatment with cyproterone acetate (see section &lsquo;Do not take Androcur&rsquo;).<br />Blood clots (thromboembolic events) have been reported in patients using<br />Androcur, although a direct link with Androcur has not been established.<br />Patients with a history of blood clots or with advanced tumors have an<br />increased risk of suffering blood clots.<br />Tell your doctor if you have ever had an arterial or venous blood clot, such<br />as a deep vein thrombosis, a clot in the lung (pulmonary embolism), a heart<br />attack (myocardial infarction) or a stroke (cerebrovascular accident).<br />If you are being treated for prostate cancer, tell your doctor if you have ever<br />suffered from any of the following as he/she will need to conduct a careful<br />evaluation before deciding to prescribe Androcur:<br />&nbsp;a blood circulation disorder (especially blood clots)<br />&nbsp;sickle cell anemia<br />&nbsp;severe diabetes with vascular changes<br />If you are being treated for the reduction of sex drive in cases of sexual<br />deviations, the effect of Androcur may be reduced under the influence of<br />alcohol.<br />Children and adolescents<br />Androcur is not recommended for use in male children and adolescents below<br />18 years of age because safety and efficacy have not been established in this<br />age group. Androcur must not be given before the end of puberty, as it may<br />have a negative effect on growth and the immature hormonal regulation<br />functions.<br />Other medicines and Androcur<br />Please tell your doctor or pharmacist if you are taking or have recently taken<br />any other medicines, including medicines obtained without a prescription.<br />Tell your doctor in particular if you are taking statins (medicines for reducing<br />blood fats), as high doses of Androcur may worsen certain side effects<br />(myopathy or rhabdomyolysis) which may occur during treatment with<br />statins.<br />Also inform your doctor if you are taking other medicines which affect the<br />liver, e.g.<br />&nbsp;ketoconazole, itraconazole, clotrimazole (for fungal infections)<br />&nbsp;ritonavir (for viral infections)<br />&nbsp;rifampicin (for tuberculosis)<br />&nbsp;phenytoin (for epilepsy)<br />&nbsp;the herbal remedy St. John&acute;s wort<br />High doses of Androcur (100 mg 3 times per day) may block certain liver<br />enzymes, which may influence the effect of other medicines.<br />Pregnancy, breast-feeding, fertility<br />Treatment with Androcur (for use in men) is not indicated in women.<br />Driving and using machines<br />Androcur can lead to tiredness and decreased energy and impair your<br />concentration.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="AdministrationRoutesEn">3. How to use this product.</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Take the tablets with some liquid after meals. Do not take more than the<br />maximum daily dose of 300 mg.<br />If you think that the effect of Androcur is too strong or too weak, talk to your<br />doctor or pharmacist.<br />Reduction of sex drive in cases of sexual deviations in men<br />Your doctor will determine the individual dosage.<br />1. Treatment is generally started with 1 tablet Androcur twice daily.<br />2. Your doctor may increase the dose to 2 tablets twice daily, or even 2<br />tablets three times daily for a short period of time.<br />3. When a satisfactory result has been achieved, your doctor will put<br />you on the lowest possible dose needed to maintain the therapeutic<br />effect. Quite often 1/2 tablet twice daily is sufficient.<br />4. When establishing the maintenance dose or when discontinuing<br />the preparation, your doctor will reduce the dosage gradually. To<br />this end, your doctor may reduce the daily dose by 1 tablet, or 1/2<br />tablet, at intervals of several weeks.<br />To stabilize the therapeutic effect it is necessary to take Androcur over a long<br />period of time. Your doctor may refer you for psychotherapy during this time.<br />Antiandrogen treatment in inoperable prostate cancer<br />The daily dose is 2 tablets Androcur twice to three times daily (= 200 ‑ 300<br />mg per day).<br />Do not change or interrupt the treatment or dosage prescribed by your doctor<br />once you feel an improvement.<br />&nbsp;To reduce the initial increase of male sex hormones resulting from<br />treatment with gonadotropin-releasing hormone (GnRH) agonists<br />1. Initially, the daily dose is 2 tablets Androcur twice daily (= 200 mg<br />per day) alone for 5 ‑ 7 days.<br />2. This is followed by 2 tablets Androcur twice daily (= 200 mg<br />per day) for 3 ‑ 4 weeks together with a GnRH agonist in the<br />dosage recommended by the marketing authorization holder (see<br />prescribing information of GnRH agonist).<br />&nbsp;To treat hot flushes in patients under treatment with GnRH analogs or<br />whose testicles have been removed (orchiectomy)<br />1. The daily dose is 1-3 tablets Androcur per day (50-150 mg per day).<br />2. If necessary the dose can be increased up to 2 tablets three times<br />daily (300 mg per day).<br />Elderly patients (65 years or older)<br />There are no data suggesting the need for a dosage adjustment in elderly<br />patients.<br />Patients with impaired liver function<br />Do not take Androcur if you suffer from impaired liver function (see section<br />&lsquo;Do not take Androcur&rsquo;).<br />Patients with impaired kidney function<br />There are no data suggesting the need for a dosage adjustment in patients<br />with impaired kidney function.<br />If you take more Androcur than you should<br />There are no reports of any harmful effects of taking too many Androcur<br />tablets.<br />If you forget to take Androcur<br />Do not take the missed Androcur tablet (do not take a double dose to make<br />up for the missed tablet). Continue taking the tablets at the regular time.<br />If you stop taking Androcur<br />The original conditions for which Androcur was prescribed by your doctor<br />may worsen. Do not stop taking Androcur unless your doctor has told you to<br />do so. If you want to stop taking Androcur, you should discuss this with your<br />doctor first.<br />If you have any further questions on the use of this product, ask your doctor<br />or pharmacist.</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsEn">4. Possible side effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Like all medicines, Androcur can cause side effects, although not everybody<br />gets them.<br />If any of the side effects gets serious, or if you notice any side effects not<br />listed in this leaflet, please tell your doctor or pharmacist.<br />Tell your doctor immediately if you notice any of the following symptoms:<br />R Generally feeling unwell, fever, nausea, vomiting, loss of appetite, itching<br />all over your body, yellowing of your skin and eyes, light colored bowel<br />movements, dark colored urine. These symptoms could be signs of liver<br />toxicity, including inflammation of the liver (hepatitis) or liver failure.<br />&nbsp;Disturbances of liver function, some of them severe (jaundice, hepatitis<br />and hepatic failure), have been observed in patients treated with<br />Androcur. At dosages of 100 mg and above also fatal cases have been<br />reported. Most reported fatal cases were in men with advanced prostate<br />cancer. The disturbances of liver function are dose-related and usually<br />develop several months after treatment has begun. Therefore, your doctor<br />will monitor your liver function before treatment and during treatment<br />especially if there are any symptoms or signs suggestive of liver toxicity.<br />If liver toxicity is confirmed, your doctor will stop your treatment with<br />Androcur, unless the liver toxicity can be explained by another cause (e.g.<br />secondary tumors). In this case your doctor may continue your treatment<br />with Androcur if the perceived benefit outweighs the risk.<br />&nbsp;Unusual upper abdominal pains which do not disappear spontaneously<br />within a short time. These symptoms could be signs of benign or<br />malignant liver tumors which may lead to life-threatening internal<br />bleeding (intra-abdominal hemorrhage).<br />&nbsp;Swelling of the calf or leg, chest pain, being short of breath or suddenly<br />feeling weak. These symptoms could be signs of formation of blood clots<br />(thromboembolic events).<br />Very common side effects: may affect more than 1 in 10 people<br />&nbsp;reversible inhibition of sperm production (spermatogenesis)<br />&nbsp;reduced sexual drive (libido decreased)<br />&nbsp;inability to achieve or maintain an erection (erectile dysfunction)<br />Common side effects: may affect up to 1 in 10 people<br />&nbsp;liver toxicity, including jaundice, inflammation of the liver (hepatitis), liver<br />failure<br />&nbsp;weight gain<br />&nbsp;weight loss<br />&nbsp;depressed mood<br />&nbsp;temporary restlessness<br />&nbsp;enlarged breasts (gynaecomastia)<br />&nbsp;tiredness (fatigue)<br />&nbsp;hot flushes<br />&nbsp;sweating<br />shortness of breath<br />Uncommon side effects: may affect up to 1 in 100 people<br />&nbsp;rash<br />Rare side effects: may affect up to 1 in 1,000 people</p><p>allergic reaction (hypersensitivity)<br />&nbsp;benign brain tumors (meningiomas) (see sections &lsquo;Do not take Androcur&rsquo;<br />and &lsquo;Warnings and precautions&rsquo;)<br />Very rare side effects: may affect up to 1 in 10,000 people<br />&nbsp;benign and malignant liver tumors<br />Side effects for which frequency is not known: frequency cannot be<br />estimated from the available data<br />&nbsp;internal bleeding (intra-abdominal hemorrhage)<br />&nbsp;formation of blood clots (thromboembolic<br />events) (see section &lsquo;Warnings<br />and precautions&rsquo;)<br />&nbsp;osteoporosis<br />&nbsp;anemia<br />Under treatment with Androcur, sexual drive and potency are reduced and<br />the function of the testicles is inhibited. These changes are reversible after<br />Androcur treatment has been discontinued.<br />Over the course of several weeks Androcur inhibits the formation of sperms<br />(spermatogenesis) as a result of the antiandrogenic and antigonadotropic<br />actions. Spermatogenesis recovers gradually within a few months after<br />Androcur treatment has been discontinued.<br />Androcur may lead to swelling of the breast gland (so called gynaecomastia,<br />sometimes combined with tenderness to touch of the mamillae) which<br />usually regresses after Androcur treatment has been discontinued.<br />As with other antiandrogenic treatments, long-term use of Androcur may<br />lead to osteoporosis.<br />Benign brain tumors (meningiomas) have been reported in association with<br />long-term use (several years) of Androcur doses of 25 mg and above (see<br />sections &lsquo;Do not take Androcur&rsquo; and &lsquo;Warnings and precautions&rsquo;).<br />If you get any side effects, talk to your doctor or pharmacist. This includes<br />any possible side effects not listed in this leaflet.<br />To report any side effect(s):<br />The National Pharmacovigilance Centre (NPC).<br />SFDA Call Center: 19999<br />E-mail: npc.drug@sfda.gov.sa<br />Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-lg-12 col-md-12 col-sm-6 col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsEn">5. How to store this product</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Keep this medicine out of the sight and reach of children.<br />Do not take this medicine after the expiry date which is stated on the pack.<br />Do not store above 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. Further information</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsEn">a. What this product contains</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>The active substance is cyproterone acetate.<br />Each tablet contains 50 mg cyproterone acetate.<br />The other ingredients are lactose monohydrate, maize starch, povidone 25,<br />colloidal anhydrous silica, magnesium stearate</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsEn">b. What this product looks like and contents of the pack</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Androcur tablets are white to faintly yellowish tablets, scored on one side,
with an embossed “BV” in a regular hexagon on the other side. The tablet can
be divided into equal halves.
Pack size: Box of 20 tablets
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingEn">c. Marketing Authorization Holder and Manufacturer</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                <p>Manufacturer<br />Bayer Weimar GmbH und Co. KG<br />99427 Weimar, Germany.<br />Marketing Authorisation Holder<br />Bayer AG<br />Kaiser-Wilhelm-Allee 1<br />51373 Leverkusen, Germany</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteEn">d. This leaflet was last revised in {MM/YYYY}</label>
        </div>
        <div class="form-group">
            <br />
            <div class="m-l-60">
                Text based on CCDS version 13 valid as per 05 May 2020
            </div>
        </div>
    </div>
</div>    </div>
    <div id="A-div" class="box-data">
<div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue  m-t-20 m-b-20 ltr">
                <i class="fa fa-info-circle"></i>&nbsp;
                <span style="font-size: large; background-color: rgb(245,245,245); color: rgb(51,51,51); "> نشرة الدواء تحت مراجعة الهيئة العامة للغذاء والدواء</span>
                <span style="font-size:small;">  (اقرأ هذه النشرة بعناية قبل البدء في استخدام هذا المنتج لأنه يحتوي على معلومات مهمة لك)</span>
            </div>
    <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr">

    </div>

</div>
<div class="clearfix rtl">
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="InventedNameAr">1. ما ھو هذا المستحضر وماھي دواعي استعماله</label>
        </div>
        <div class="form-group clearfix" style="float: right">
            <br />
            <p>اندروكيور مستحضر هرموني له تأثير مضاد للهرمونات الذكرية )مضاد لهرمون الأندروجين(.<br />المادة الفعالة هي أسيتات السيبروتيرون<br />يخفض اندروكيور تركيز التستوستيرون )هرمون الأندروجين( في الدم. ذلك يؤدي إلى انخفاض<br />الرغبة الجنسية.<br />تحفز الأندروجينات نمو سرطان البروستات. يثبط )يمنع( اندروكيور هذا التأثير لدى هؤلاء المرضى.<br />يستخدم اندروكيور في الحالات الآتية<br />r تخفيض الرغبة الجنسية في حالات الانحرافات الجنسية لدى الرجال<br />r علاج مضاد لهرمون الأندروجين في حالات سرطان البروستات الغير قابلة للجراحة.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="form-group clearfix">
            <label class="h2" for="PrecautionsAr">2. ما الذي يجب عليك معرفته قبل استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لا تتناول اندروكيور<br />لا تتناول اندروكيور إذا كان لديك أي من الحالات المذكورة أدناه. إذا كانت أي من هذه الحالات<br />تنطبق عليك أبلغ طبيبك قبل البدء في تناول اندروكيور. عندما يتم وصفه لتخفيض الرغبة<br />الجنسية في حالات الانحرافات الجنسية لدى الرجال<br />r إذا كان لديك أمراض في الكبد<br />r إذا كنت تعاني من اضطرابات وراثية لوظيفة الكبد مع وجود خلل في إزالة صباغ خلايا الدم<br />الحمراء التي تسمى بيليروبين )متلازمة دوبين-جونسون أو متلازمة روتور(<br />r إذا كان لديك الآن أو في أي وقت مضى ورم كبدي حميد أو خبيث<br />r إذا كان لديك الآن أو في أي وقت مضى ورم حميد في الدماغ )ورم سحائي(<br />r إذا كان لديك مرض يسبب هزال )مرض يسبب وهن أو فقدان النشاط(<br />r إذا كنت تعاني من اكتئاب مزمن وخيم.<br />r إذا كان لديك الآن أو في أي وقت مضى اضطراب يؤثر على الدورة الدموية: خاصة، في<br />الحالات المرتبطة بالجلطة الدموية )تكون جلطات دموية( داخل الأوردة الدموية )عملية تكون<br />الجلطات الدموية(<br />r إذا كان لديك داء سكري وخيم )السكري( مع تغييرات في الأوعية الدموية،<br />r إذا كان لديك فقر الدم المنجلي،<br />r إذا كان لديك حساسية زائدة لأسيتات السبرتيرون أو لأي من المكونات الأخرى في اندروكيور<br />عندما يتم وصف اندروكيور كعلاج مضاد لهرمون الأندروجين في حالات سرطان البروستات الغير<br />قابلة للجراحة<br />r إذا كان لديك مرض في الكبد<br />r إذا كنت تعاني من اضطرابات وراثية لوظيفة الكبد مع وجود خلل في إزالة صباغ خلايا الدم<br />الحمراء التي تسمى بيليروبين )متلازمة دوبين-جونسون أو متلازمة روتور(<br />r إذا كان لديك الآن أو في أي وقت مضى ورم في الكبد حميد أو خبيث )فقط إذا كانت هذه<br />الأورام ليست بسبب انتقال العامل المسبب للورم من مقره الأساسي الذي هو سرطان<br />البروستات إلى جزء آخر من الجسم الذي هو الكبد(<br />r إذا كان لديك الآن أو في أي وقت مضى ورم حميد في الدماغ )ورم سحائي(<br />r إذا كان لديك مرض يسبب هزال )مرض يسبب وهن أو فقدان النشاط، مع استثناء سرطان<br />البروستات الغير قابل للجراحة<br />r إذا كنت تعاني من اكتئاب مزمن وخيم.<br />r إذا كان لديك اضطراب يؤثر على الدورة الدموية: خاصة، في الحالات المرتبطة بالجلطة<br />الدموية )تكون جلطات دموية( داخل الأوردة الدموية )عملية تكون الجلطات الدموية(<br />r إذا كان لديك حساسية زائدة لأسيتات السبرتيرون أو لأي من المكونات الأخرى في اندروكيور<br />التحذيرات والاحتياطات<br />أبلغ طبيبك إذا كنت تعاني من الداء السكري، لأنه هو / هي يمكن أن يحتاج لتعديل العلاج<br />المضاد للداء السكري. هذا يحتاج لمراقبة دقيقة خلال العلاج باندروكيور )أنظر أيضاً الجزء &laquo;لا<br />تتناول اندروكيور .)&raquo;<br />تم التبليغ عن حالات أنيميا خلال العلاج باندروكيور. لذلك، سوف يراقب طبيبك خلال العلاج<br />تعداد خلايا الدم الحمراء.<br />البيانات الناتجة من الدراسات على الحيوانات تقترح أن الجرعات العالية من اندروكيور يمكن أن<br />تقلل وظيفة الغدة المرتبطة بالكلى و التي تنتج الهرمون )غدد الكظر &ndash; فوق الكلية(. لذلك<br />يمكن لطبيبك أن يجري بعض الاختبارات لمراقبة هذا التأثير أثناء العلاج باندروكيور.<br />تم ربط استخدام أسيتات سيبروتيرون بتطور ورم دماغي حميد بشكل عام )الورم السحائي(.<br />يزداد الخطر خاصة عند استخدامه لمدة طويلة )عدة سنوات( أو لفترة أقصر مع جرعات عالية<br />) 25 مجم في اليوم وما فوق(. إذا لاحظت أي أعراض مثل تغيرات في الرؤية )مثل رؤية مزدوجة أو<br />ضبابية(، فقدان السمع أو طنين في الأذنين، فقدان حاسة الشم، الصداع الذي يتفاقم مع مرور<br />الوقت، فقدان الذاكرة، نوبات مرضية، ضعف في ذراعيك أو ساقيك، يجب عليك إبلاغ طبيبك<br />على الفور. إذا تم تشخيص إصابتك بالورم السحائي ، سيتوقف طبيبك عن علاجك باستخدام<br />أسيتات سيبروتيرون )انظر قسم &laquo;لا تتناول أندروكيور .)&raquo;<br />تم التبليغ عن حدوث جلطات دموية )حالات تجلط دموي( لدي مرضى تتناول اندروكيور، مع أنه لم<br />يتم أثبات وجود علاقة مباشرة مع اندروكيور. المرضى الذين لديهم تاريخ مرضي لجلطات الدموية<br />أو أورام متقدمة لديهم زيادة في مخاطرة المعاناة من جلطات الدم. ابلغ طبيبك إذا كنت قد<br />عانيت في أي وقت من جلطة دموية في شريان أو وريد، مثل جلطة دموية داخل وريد عميق،<br />جلطة في الرئة )انصمام رئوي(، نوبة قلبية )احتشاء القلب( أو صدمة )حادثة دماغية وعائية(.<br />ابلغ طبيبك، إذا تم معالجتك من سرطان البروستات، أو إذا عانيت في أي وقت من أية من الحالات<br />الآتية لأن الطبيب أو الطبيبة سيحتاج إلى إجراء تقييم حذر قبل اتخاذ قرار وصف اندروكيور:<br />r اضطراب الدورة الدموية )خاصة جلطات دموية(<br />r فقر دم منجلي<br />r داء سكري وخيم مع تغيرات وعائية<br />إذا تم معالجتك لتخفيض الرغبة الجنسية في حالات الانحرافات الجنسية، فاعلية اندروكيور يمكن<br />أن تنخفض تحت تأثير الكحول.<br />الأطفال والمراهقين<br />لا نوصي بتناول اندروكيور لدى الأطفال و المراهقين الذكور الذين يقل اعمارهم عن 18 سنة،<br />لعدم إثبات الأمان و الفاعلية لهذه المجموعة العمرية. يجب عدم تناول اندروكيور قبل تمام البلوغ،<br />لأنه يمكن أن يكون له آثار سلبية على النمو و على الوظائف الغير ناضجة لتنظيم الهرمونات.<br />الأدوية الأخرى و اندروكيور<br />الرجاء، ابلاغ طبيبك أو الصيدلي، إذا كنت تتناول حالياً أو قد تناولت حديثاً أية أدوية أخرى،<br />تشمل الأدوية التي تصرف بدون وصفة طبية. ابلغ طبيبك إذا كنت تتناول خاصة أدوية من<br />مجموعة الستاتين )أدوية لتخفيض دهون الدم(، لأن الجرعات العالية من اندروكيور يمكن أن تجعل<br />بعض الآثار الجانبية أسوأ )اعتلال عضلي أو انحلال الربيدات( التي يمكن أن تحدث أثناء العلاج<br />بالستاتين. أيضاً أبلغ طبيبك إذا كنت تتناول أدوية أخرى التي لديها تأثير على الكبد، مثل<br />r كيتوكونازول، ايتراكونازول، كلوتريمازول )لعدوى فطرية(،<br />r ريتونافير )لعدوى فيروسية(<br />r ريفامبيسين )للدرن(،<br />r فنيتوين )للصرع(<br />r علاج عشبي، عشبة سان جون.<br />يمكن للجرعات العالية من اندروكيور ) 100 ميليغرام 3 مرات يومياً( أن تعوق بعض أنزيمات الكبد،<br />التي يمكن أن تكون لديها تأثير على مفعول أدوية أخرى.<br />الحمل، الرضاعة و الخصوبة<br />العلاج باندروكيور )لاستخدام الرجال( لا يُوَصى باسْتِعْمالِه فى السيدات.<br />القيادة و استخدام الماكينات<br />يمكن أن يؤدي اندروكيور لتعب و إنخفاض الطاقة و يسبب خلل في التركيز</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            https://localhost:44358/Dashboard
            <label class="h2" for="AdministrationRoutesAr">3. ماھي طريقة استعمال هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>تناول الأقراص بعد الوجبات، مع كمية وفيرة من سائل.<br />لا تتناول أكثر من الجرعة اليومية القصوى التي هي 300 ميليغرام.<br />إذا كنت تعتقد أن آثار اندروكيور شديدة جداً أو ضعيفة جداً، أبلغ طبيبك أو الصيدلي.<br />تخفيض الرغبة الجنسية في حالات الانحرافات الجنسية لدى الرجال<br />سوف يحدد طبيبك الجرعة الفردية.<br />1 - يبدأ عامة العلاج بتناول 1 قرص اندروكيور مرتين يومياً.<br />2 - يمكن لطبيبك زيادة الجرعة إلى 2 قرص مرتين يومياً، أو حتى 2 قرص ثلاثة مرات يومياً<br />لفترة زمنية قصيرة.<br />3 - عندما يتم تحقيق نتائج مرضية، سوف يغير طبيبك الجرعة لتكون أقل جرعة ممكنة<br />للحفاظ على التأثير العلاجي. في كثير من الاحيان يمكن الاكتفاء بنصف قرص مرتين<br />يومياً.<br />4 - سوف يخفض طبيبك الجرعة تدريجياً، عندما تقرر جرعة استمرار العلاج أو عندما يتم<br />التوقف عن العلاج. في النهاية، سوف يخفض طبيبك الجرعة اليومية بعدد 1 قرص أو<br />نصف قرص، على فترات تتكون من عدة أسابيع.<br />لتثبيت التأثير العلاجي من الضرورة تناول اندروكيور خلال فترة زمنية طويلة.<br />يمكن لطبيبك أن يطلب منك اللجوء لمعالجة نفسية خلال هذه الفترة.<br />علاج مضاد لهرمون الأندروجين في حالات سرطان البروستات الغير قابلة للجراحة.<br />الجرعة اليومية هي 2 قرص اندروكيور من مرتين إلى ثلاثة مرات يومياً )= 200 &ndash; 300 ميليغرام<br />في اليوم(.<br />يجب عدم التغيير أو التوقف عن العلاج أو الجرعة الموصوفة من طبيبك عندما يتم الاحساس<br />بتحسن حالتك.<br />r لتخفيض الزيادة المبدئية للهرمونات الجنسية الذكرية الناتجة عن العلاج بهرمونات<br />مناهضة لتنشيط الخصيتين لإنتاج الحيوانات المنوية عند الذكور ) .)GnRH<br />1 - في بداية العلاج، الجرعة اليومية هي 2 قرص اندروكيور مرتين يومياً )= 200 ميليغرام<br />يومياً( بمفردها لمدة 5 &ndash; 7 أيام.<br />2 - يتبع ذلك 2 قرص اندروكيور مرتين يومياً )= 200 ميليغرام يومياً( لمدة 3 &ndash; 4 أسابيع<br />بالإضافة إلى هرمونات مناهضة لتنشيط الخصيتين لإنتاج الحيوانات المنوية عند الذكور<br />GnRH( ( بالجرعة الموصى بها من حامل تصريح التسويق )أنظر المعلومات الخاصة بوصف<br />هرمونات مناهضة لتنشيط الخصيتين لإنتاج الحيوانات المنوية عند الذكور ) .))GnRH<br />r لعلاج التوهج الساخن لدى مرضى يخضعون لعلاج مماثل لهرمونات مناهضة لتنشيط<br />الخصيتين لإنتاج الحيوانات المنوية عند الذكور ) GnRH ( أو تم استئصال الخصيتين لهم.<br />1 - الجرعة اليومية هي 1 &ndash; 3 قرص اندروكيور يومياً ) 50 &ndash; 150 ميليغرام يومياً(.<br />2 - عند الضرورة يمكن زيادة الجرعة لتصل إلى 2 قرص ثلاثة مرات يومياً ) 300 ميليغرام يومياً(.<br />المرضى كبار السن ) 65 سنة أو أكثر(لا توجد بيانات تقترح الاحتياج لتعديل الجرعة في المرضى كبار السن.<br />مرضى لديهم اختلال لوظائف الكبد<br />لا تتناول اندروكيور إذا كنت تعاني من خلل لوظائف الكبد )أنظر الجزء &laquo;لا تتناول اندروكيور .)&raquo;<br />مرضى لديهم خلل لوظائف الكلى<br />لا توجد بيانات تقترح الاحتياج لتعديل الجرعة في مرضى لديهم خلل لوظائف الكلى.<br />إذا تناولت اندروكيور أكثر مما يجب<br />لا توجد تقارير عن أية آثار ضارة من تناول أقراص اندروكيور بكمية أكثر مما ينبغي<br />إذا نسيت تناول اندروكيور<br />لا تتناول قرص اندروكيور المنسي )لا تتناول جرعة مضاعفة لتصحيح نسيان القرص(.<br />استمر في تناول الأقراص في توقيت منتظم.<br />إذا توقفت عن تناول اندروكيور<br />الحالات الأصلية، التي وصف طبيبك اندروكيور من أجل علاجها، يمكن أن تصبح أسوأ.<br />لا تتوقف عن تناول اندروكيور إلا إذا أبلغك طبيبك بالتوقف عن العلاج.<br />إذا كنت ترغب فى التوقف عن تناول اندركيور، يجب عليك مناقشة ذلك أولاً مع طبيبك.<br />إذا كان لديك أية أسئلة إضافية أخرى، اسأل طبيبك أو الصيدلي.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="SideEffectsAr">4. الأعراض الجانبية المحتملة</label>
        </div>
        <div class="m-r-60">
            <p>مثل كل الأدوية، يمكن أن يسبب اندروكيور آثار جانبية، برغم أنه لا يصاب بها كل الأشخاص.<br />إذا اصبحت أية من الآثار الجانبية خطيرة، أو إذا لاحظت أية آثار جانبية غير مذكورة في هذه<br />النشرة، الرجاء إبلاغ طبيبك أو الصيدلي.<br />أبلغ فوراً طبيبك إذا لاحظت إية من الأعراض الآتية:<br />r عامة الاحساس باعتلال الصحة، ارتفاع درجة حرارة الجسم، غثيان، قيء، فقدان الشهية<br />للأكل، حكة للجسم بالكامل، اصفرار الجلد و العينين، براز فاتح اللون، بول غامق اللون. يمكن<br />لهذه الاعراض أن تكون علامات لتسمم الكبد، تشمل التهاب الكبد أو فشل الكبد.<br />r تم ملاحظة، اضطرابات لوظائف الكبد، بعض منها شديد )يرقان، التهاب الكبد و فشل<br />الكبد(، لدى مرضى يتم علاجهم باندروكيور. تم التبليغ أيضاً عن حالات وفاة عند جرعات<br />100 ميليغرام و أعلى من ذلك. معظم حالات الوفاة التي تم التبليغ عنها كانت في الرجال<br />الذين لديهم سرطان متقدم للبروستات.اضطرابات وظائف الكبد مرتبطة بالجرعة و تتطور<br />عادة بعد عدة شهور من بدية العلاج. لذلك، سوف يراقب طبيبك وظيفة الكبد قبل العلاج<br />و أثنائه خاصة إذا كان هناك أية أعراض أو علامات توحي بتسمم للكبد. إذا تم إثبات تسمم<br />الكبد، سوف يوقف طبيبك العلاج بتناول اندروكيور، إلا إذا أمكن تفسير تسمم الكبد<br />بسبب آخر )مثل أورام ثانوية(. في هذه الحالة يمكن لطبيبك أن يطلب الاستمرار في العلاج<br />بتناول اندروكيور في حالة تفهمه أن فوائد العلاج تفوق المخاطرة.<br />r آلاَمٌ غير معتادة في الجزء الأعلى من البطن و التي لا تختفي من تلقاء نفسها خلال فترة<br />قصيرة. هذه الأعراض يمكن أن تكون علامات لأورام حميدة أو خبيثة للكبد التي يمكن أن<br />تؤدي لنزيف داخلي )نزيف داخل البطن( يهدد الحياة.<br />r تورم الجزء الخلفي من الرجل الواقع تحت الركبة أو تورم الرجل، ألم في الصدر، صعوبة<br />التنفس أو احساس مفاجئ بالإرهاق. هذه الأعراض يمكن أن تكون علامات لتكون جلطات<br />دموية )حالات تجلط للدم(.</p><p>&nbsp;</p><p>الآثار الجانبية الشائعة جداً: يمكن أن تصيب أكثر من 1 من كل 10 أشخاص<br />r يحدث تثبيط قابِلٌ للإِصْلاَح لتكون الخلايا النطفية )إنطاف(<br />r انخفاض الرغبة الجنسية )انخفاض الشهوة الجنسية(<br />r عدم القدرة على تحقيق أو المحافظة على الانتصاب )اختلال في وظيفة الانتصاب(<br />آثار جانبية شائعة: يمكن للإصابة أن تصل إلى 1 من كل 10 أشخاص<br />r تسمم الكبد، تشمل على يرقان، التهاب الكبد، فشل الكبد<br />r زيادة الوزن<br />r فقدان الوزن<br />r أمزجة مكتئبة<br />r قلق وقتي<br />r تورم غدد الثدي في المرضى الذكور )تثدي الرجل(<br />r ارهاق )تعب(<br />r توهج ساخن<br />r التعرق<br />r صعوبة التنفس<br />آثار جانبية غير شائعة: يمكن للإصابة أن تصل إلى 1 من كل 100 شخص<br />r حكة<br />آثار جانبية نادرة: يمكن للإصابة أن تصل إلى 1 من كل 1000 شخص<br />r تفاعل حساسية زائدة<br />r أورام حميدة في الدماغ )ورم سحائي( )أنظر الأجزاء &laquo;لا تتناول اندروكيور &raquo; و &laquo;التحذيرات و<br />الاحتياطات )&raquo;<br />آثار جانبية نادرة جداً: يمكن للإصابة أن تصل إلى 1 من كل 10000 شخص<br />r أورام كبد حميدة و خبيثة<br />غير معروف تكرار الآثار الجانبية الآتية: لا يمكن تقدير التردد من البيانات المتاحة<br />r نزيف داخلي )نزيف داخل البطن(<br />r تكون جلطات دموية )حالات تجلط الدم( )أنظر الجزء &laquo;التحذيرات و الاحتياطات )&raquo;<br />r هشاشة العظام<br />r أنيميا )فقر الدم(<br />يحدث انخفاض للرغبة و القدرة الجنسية و يتم تثبيط وظيفة الخصيتين تحت تأثير علاج<br />اندروكيور.<br />هذه التغيرات يتم استعادتها لحالتها السابقة بعد التوقف عن العلاج باندروكيور.<br />خلال فترة العلاج لمدة عدة أسابيع يثبط اندروكيور تكون الخلايا النطفية )إنطاف( نتيجة للتأثير<br />المضاد لهرمون الأندروجين و مضاد للهرمونات المناهضة لتنشيط الخصيتين لإنتاج الحيوانات المنوية<br />عند الذكور.<br />يتم استعادة تكون الخلايا النطفية تدريجياً خلال بضعة شهور بعد التوقف عن العلاج<br />باندروكيور.<br />يمكن أن يؤدي اندروكيور لتورم غدد الثدي )التي تسمى تثدي الرجل، مصحوبة أحياناً بتوتر في<br />الثديين عندما يتم ملامسة الحلمتين( و التي عادة ترتد بعد التوقف عن العلاج باندروكيور.<br />كما هو الحال مع العلاجات الأخرى المضادة لهرمون الأندروجين، يمكن أن يؤدي تناول اندروكيور<br />لفترة زمنية طويلة إلى هشاشة العظام.<br />تم التبليغ عن حدوث أورام حميدة في الدماغ )ورم سحائي( مع تناول لفترة طويلة )عدة أعوام(<br />لجرعات اندروكيور 25 ميليغرام و أكثر )أنظر الأجزاء &laquo;لا تتناول اندروكيور &raquo; و &laquo;التحذيرات و<br />الاحتياطات .)&raquo;<br />إذا تم إصابتك بأي آثار جانبية، أبلغ طبيبك. هذا يشمل أي آثار جانبية محتملة غير مذكورة في<br />هذه النشرة.<br />للإبلاغ عن الأعراض الجانبية:<br />المركز الوطني للتيقظ الدوائي<br />مركز اتصال الهيئة العامة للغذاء والدواء: 19999<br />البريد الالكتروني: npc.drug@sfda.gov.sa<br />الموقع الالكتروني: https://ade.sfda.gov.sa</p>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label class="h2" for="StorageConditionsAr">5. طريقة تخزين المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>احفظ هذا الدواء بعيدًا عن أنظار ومتناول أيدي الأطفال.<br />لا تتناول هذا الدواء بعد تاريخ انتهاء المفعول المذكور على العبوة.<br />يحفظ في درجة حرارة لا تزيد عن 25 درجة مئوية.</p>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: right">6. معلومات أخرى</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="IngredientsAr">أ‌. على ماذا يحتوي هذا المستحضر</label>
        </div>
        <div class="m-r-60">
            <p>لمادة الفعالة هي أسيتات السبروتيرون.<br />كل 1 قرص يحتوي على 50 ميليغرام أسيتات السبروتيرون.<br />المكونات الآخرى هي لاكتوز احادي المائية، نشاء الذرة، بوفيدون 25 ، سيليكا غروانية لا مائية،<br />ستيارات المغنيزيوم<br />&nbsp;</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ShapeAndContentsAr">ب‌. كيف يبدو شكل هذا المستحضر وماهي محتويات العلبة</label>
        </div>
        <div class="m-r-60">
            <p>أقراص اندروكيور لونها يتراوح من اللون الأبيض إلى اللون الأصفر الفاتح و لديها على أحد<br />وجهيها حز على شكل خط لتجزئتها وبارِز على وجهها الآخر داخل مضلع سداسي منتظم<br />&raquo;BV&laquo; . يمكن تقسيم القرص لنصفين متساويين.<br />حجم العبوة: علبة بها 20 قرص</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="ManufacturingAndMarketingAr">ت‌. الشركة المصنعة ومالك حق التسويق</label>
        </div>
        <div class="m-r-60">
            <p>لمصنع<br />باير فايمر جي أم بي اتش أند كو. كي جي<br />99427 - فايمر، ألمانيا.<br />حامل تصريح التسويق<br />باير ايه جي<br />1 طريق القيصر ويلهلم،<br />51373 ليفركوزن، ألمانيا</p>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label class="h2" for="RevisionNoteAr">ث‌. تمت مراجعة هذه النشرة في التاريخ الذي تمت فيه مراجعة النشرة بالشهر والسنة</label>
        </div>
        <div class="m-r-60">
            هذا النص يعتمد على CCDS رقم 13 معتمد بتاريخ 5 مايو 2020 .
        </div>
    </div>
</div>
    </div>
    <div id="M-div" class="box-data">


    <div class="p-20 text-center font-22">
            <div class="p-10 bg-light-blue font-15 m-t-20 m-b-20 ltr"><i class="fa fa-info-circle"></i>&nbsp;Read this leaflet carefully before you start using this product as it contains important information for you</div>
    </div>
<div class="row clearfix ltr">

    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="MedicinalName">1. NAME OF THE MEDICINAL PRODUCT </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Androcur 50 mg tablets
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="QualitativeQuantitativeComposition">2. QUALITATIVE AND QUANTITATIVE COMPOSITION </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                1 tablet contains 50 mg cyproterone acetate (CPA).

Excipients with known effect: each tablet contains 103 mg of lactose as lactose monohydrate (see section 4.4).

For the full list of excipients, see section 6.1.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="DosageForm">3. PHARMACEUTICAL FORM </label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Tablet
White to pale yellow tablets with a breaking score line on one side and embossed with ‘BV’ in a regular hexagon on the other. The tablet can be divided into equal doses.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">4. CLINICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="TherapeuticIndications">4.1 Therapeutic Indications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>In men</u></p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->for the palliative treatment of metastasising or locally advanced, inoperable prostate carcinoma</p><p style="margin-left:85.05pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->if treatment with LHRH analogues or surgical intervention has proven inadequate, is contraindicated or oral therapy is given preference.</p><p style="margin-left:85.05pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->initially for the prevention of undesired sequelae and complications which can be caused at the start of treatment with LHRH agonists by the initial increase in serum testosterone.</p><p style="margin-left:85.05pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->for the treatment of hot flushes, which occur during treatment with LHRH agonists or following an orchiectomy.</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->sexual-drive suppression in the event of hypersexuality and sexual deviations.</p><p style="margin-left:28.35pt">Cyproterone acetate 50&nbsp;mg can be used for sexual-drive suppression in the event of hypersexuality and sexual deviations where other therapies are considered unsuitable.</p><p style="margin-left:28.35pt">&nbsp;</p><p><u>In women</u></p><p>Severe to very severe androgenisation symptoms such as</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe forms of increased facial and body hair caused by androgens (severe hirsutism),</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]-->severe forms of loss of scalp hair (androgenetic alopecia), often associated with severe forms of acne and/or seborrhoea,</p><p>&nbsp;</p><p>&nbsp;</p><p>Cyproterone acetate 50&nbsp;mg is indicated for severe to very severe androgenisation symptoms in women, where satisfactory results could not be obtained with medicinal products containing low-dose cyproterone or with other treatment options.</p><p>&nbsp;</p><p><strong>Note</strong>: Pregnant women may not take Androcur. Consequently, pregnancy has to be excluded prior to treatment. Androcur has to be combined with a suitable oestrogen or a suitable progestogen-oestrogen combination in fertile women, in order to avoid menstrual-cycle disturbances.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PosologyAndMethodAdministration">4.2 Posology And Method Administration</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Dosage</u></p><p>The tablets should be taken with some liquid after meals.</p><p>&nbsp;</p><p><u>Use in men</u></p><p>The maximum daily dose is 300&nbsp;mg.</p><p>&nbsp;</p><p style="margin-left:0in"><em>Sex-drive suppression in the event of hypersexuality and sexual deviations</em></p><p>The duration of treatment has to be individually specified. Sometimes, a therapeutic effect can set in after a few weeks; however, it can also take several months until any treatment success is noticed.</p><p>&nbsp;</p><p>The initial dose is generally 1&nbsp;tablet twice daily (=&nbsp;100&nbsp;mg). If there has been no improvement after about four weeks, the dose can be increased to two tablets, twice daily (=&nbsp;200&nbsp;mg) or temporarily even to two tablets thrice daily (=&nbsp;300&nbsp;mg).</p><p>&nbsp;</p><p>When a satisfactory treatment result has been reached, it should be attempted to manage with the lowest possible dose. Often, &frac12; of a tablet twice daily is sufficient (=&nbsp;50&nbsp;mg).</p><p>&nbsp;</p><p>When adjusting to a maintenance dose and when discontinuing the product, the dose has to be reduced or discontinued gradually. The daily dose should be decreased by 1&nbsp;tablet (=&nbsp;50&nbsp;mg) or better &frac12; (=&nbsp;25&nbsp;mg) of a tablet in intervals of a few weeks each.</p><p>&nbsp;</p><p>In order to stabilise the therapeutic effect, it is necessary to administer Androcur 50&nbsp;mg over a prolonged period, if possible with simultaneous application of psychotherapeutic measures.</p><p>&nbsp;</p><p>The duration of treatment with cyproterone acetate should be determined on an individual basis. If a satisfactory outcome is attained, the therapeutic effect should be maintained with the lowest possible dose. A change in dose or discontinuation of cyproterone acetate should be undertaken gradually.</p><p>&nbsp;</p><p style="margin-left:0in"><em>Anti-androgen treatment of prostate carcinoma</em></p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Palliative therapy of metastasising or locally advanced, inoperable prostate carcinoma without orchiectomy or treatment with LHRH agonists</em></p><p style="margin-left:28.35pt">Two tablets 2 to 3&nbsp;times daily (=&nbsp;200 to 300&nbsp;mg).</p><p style="margin-left:28.35pt">In the event of improvement or remission, therapy should neither be discontinued nor the dose reduced.</p><p>&nbsp;</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>Initially for the prevention of undesired sequelae and complications which can be caused at the start of treatment with LHRH agonists by the initial increase in serum testosterone</em></p><p style="margin-left:28.35pt">First, 2&nbsp;tablets alone twice daily for 5 to 7&nbsp;days (=&nbsp;200 mg) Androcur 50&nbsp;mg, then 2&nbsp;tablets twice daily for 3 to 4&nbsp;weeks (=&nbsp;200 mg) Androcur 50&nbsp;mg together with an LHRH agonist in the dosage designated by the marketing authorisation holder.</p><p style="margin-left:28.35pt">The instructions in the package leaflet of the product used during treatment with LHRH agonists are to be followed.</p><p>&nbsp;</p><p style="margin-left:28.35pt; text-indent:-28.35pt"><!--[if !supportLists]-->-&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; <!--[endif]--><em>for the treatment of hot flushes, which occur during treatment with LHRH agonists or following an orchiectomy</em></p><p style="margin-left:28.35pt">The recommended dose is 1 to 3&nbsp;tablets (50 to 150&nbsp;mg) daily. It can be increased up to 2&nbsp;tablets three times daily (=&nbsp;300&nbsp;mg), when required.</p><p>&nbsp;</p><p><u>Use in women</u></p><p><strong>&nbsp;</strong></p><p style="margin-left:0in"><em>Women of childbearing age with a regular menstrual cycle</em></p><p>Treatment is started in sexually mature women on day&nbsp;1 of their cycle (first day of menstruation = first day of the cycle).</p><p>Two tablets of Androcur (=&nbsp;100&nbsp;mg) are to be taken daily from day&nbsp;1 to day&nbsp;10 of the cycle, if possible at a specific time, in order to reduce the risk of forgetting to take them. In addition, a suitable oestrogen or suitable progestogen-oestrogen combination with the lowest possible content of ethinyl oestradiol, such as 30 or 35&nbsp;&micro;g, has to be used each day from day&nbsp;1 to day&nbsp;21 of the menstrual cycle, in order to stabilise the cycle of the patient and to provide the necessary contraceptive protection</p><p><img src="data:image/png;base64,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" /></p><p><!--[if gte vml 1]><v:shapetype
 id="_x0000_t75" coordsize="21600,21600" o:spt="75" o:preferrelative="t"
 path="m@4@5l@4@11@9@11@9@5xe" filled="f" stroked="f">
 <v:stroke joinstyle="miter"/>
 <v:formulas>
  <v:f eqn="if lineDrawn pixelLineWidth 0"/>
  <v:f eqn="sum @0 1 0"/>
  <v:f eqn="sum 0 0 @1"/>
  <v:f eqn="prod @2 1 2"/>
  <v:f eqn="prod @3 21600 pixelWidth"/>
  <v:f eqn="prod @3 21600 pixelHeight"/>
  <v:f eqn="sum @0 0 1"/>
  <v:f eqn="prod @6 1 2"/>
  <v:f eqn="prod @7 21600 pixelWidth"/>
  <v:f eqn="sum @8 21600 0"/>
  <v:f eqn="prod @7 21600 pixelHeight"/>
  <v:f eqn="sum @10 21600 0"/>
 </v:formulas>
 <v:path o:extrusionok="f" gradientshapeok="t" o:connecttype="rect"/>
 <o:lock v:ext="edit" aspectratio="t"/>
</v:shapetype><v:shape id="Picture_x0020_1" o:spid="_x0000_i1025" type="#_x0000_t75"
 alt="Bild" style='width:253.5pt;height:112.5pt;visibility:visible;
 mso-wrap-style:square'>
 <v:imagedata src="file:///C:/Users/GGQDY/AppData/Local/Temp/msohtmlclip1/01/clip_image001.jpg"
  o:title="Bild"/>
</v:shape><![endif]--><!--[if !vml]--><!--[endif]--></p><p>This is followed by a seven-day break, during which withdrawal bleeding occurs. Four weeks after having started taking the tablets, i.e. on the same day of the week, the next combined treatment is started, irrespective of whether the bleeding has already stopped or is still ongoing. If there has not been any bleeding, pregnancy has to be ruled out prior to continuing treatment.</p><p>&nbsp;</p><p>After clinical improvement, the daily Androcur dose can be reduced during the first 10&nbsp;days of combination treatment to 1 (=&nbsp;50&nbsp;mg) or &frac12;&nbsp;tablet (=&nbsp;25&nbsp;mg), or combination treatment continued with Androcur 10&nbsp;mg tablets. Perhaps even an anti-androgenic progestogen-oestrogen combination alone will suffice.</p><p>&nbsp;</p><p>Since women may not become pregnant while receiving Androcur 50&nbsp;mg, they must properly adhere to the treatment regimen (see above). Conception protection can be expected only if there has been no deviation from a 24‑hour schedule of use.</p><p>&nbsp;</p><p style="margin-left:0in"><em>Women of childbearing age with an irregular menstrual cycle or amenorrhoea</em></p><p>After pregnancy has been ruled out, treatment may begin immediately according to prescription. As opposed to women of childbearing age who have a regular menstrual cycle, there is no reliable protection against pregnancy as of day&nbsp;1 of treatment.</p><p>Up to day&nbsp;14 of taking a daily contraceptive, additional mechanical contraception (e.g. by using a condom) will have to be used. Day&nbsp;1 of treatment will be regarded as day&nbsp;1 of the menstrual cycle. Further treatment follows as described for women with a regular menstrual cycle. During the tablet-free break, there will probably be withdrawal bleeding.</p><p>&nbsp;</p><p><em>Reaction to missed tablets</em></p><p>If pregnancy is suspected, or after a lengthy tablet-free break, the treatment may only be restarted after pregnancy has been ruled out (see section&nbsp;4.4).</p><p>&nbsp;</p><p>Women, who are taking the oral contraceptive concomitantly with Androcur tablets, should take the tablets at a specific time.</p><p>&nbsp;</p><p>If Androcur 50&nbsp;mg and (or) the oestrogen or the progestogen-oestrogen combination have been missed, they must be taken within 12&nbsp;hours of the usual time. The contraceptive effect becomes questionable if more than 36&nbsp;hours have elapsed since the previous administration. Forgetting to take Androcur 50&nbsp;mg can result in reduced efficacy and intermenstrual bleeding. The missed Androcur tablet(s) shall not be taken (a double dose may not be taken to make up for the forgotten tablet(s)). The oestrogen or progestogen-oestrogen combination shall be continued on schedule to avoid premature withdrawal bleeding. Following the usual seven-day, tablet-free break, the combination treatment is then to be restarted as prescribed.</p><p>&nbsp;</p><p>If, however, withdrawal bleeding does not occur during the break, pregnancy has to be reliably excluded prior to starting the tablets again.</p><p>&nbsp;</p><p>The advice and recommendations contained in the package leaflet and in the summary of product characteristics of the oestrogen or the progestogen-oestrogen combination, being used, have to be followed (above all with regard to the reliability of contraceptives and recommendations in the event of forgetting to take the tablets).</p><p>&nbsp;</p><p style="margin-left:0in"><em>Post-hysterectomy or post-menopausal women</em></p><p>Androcur 50&nbsp;mg may be administered alone to patients who have had a hysterectomy or have gone through menopause. Depending upon the severity of the complaints, the dose is &frac12; to 1&nbsp;tablet (=&nbsp;25 to 50&nbsp;mg) daily, according to the tablet-taking schedule of 21&nbsp;days and a 7‑day break.</p><p>&nbsp;</p><p>The risks and benefits of treatment with Androcur 50&nbsp;mg should be re-evaluated at the start of the menopause. Long-term treatment (over the course of years) with Androcur 50&nbsp;mg should be avoided (see section&nbsp;4.4 Meningiomas).</p><p><u>&nbsp;</u></p><p><u>Additional information on special populations</u></p><p><strong><em>&nbsp;</em></strong></p><p><em>Children and adolescents</em></p><p>Androcur 50&nbsp;mg should not be used in male children and adolescents younger than 18&nbsp;years of age, since no data on efficacy and tolerability exist for this age group.</p><p>The safety and efficacy of Androcur 50&nbsp;mg in female children and adolescents under 18&nbsp;years has not been investigated.</p><p>Androcur 50&nbsp;mg may not be used in male and female patients prior to the end of puberty, since an undesirable effect on the endocrine system and growth in length cannot be ruled out.</p><p>&nbsp;</p><p><em>Geriatric Patients</em></p><p>The pharmacokinetics of cyproterone acetate in elderly patients has not been investigated.</p><p>&nbsp;</p><p><em>Patients with liver disease</em></p><p>The use of Androcur 50&nbsp;mg is contraindicated in patients with liver disease for as long as the liver values have not returned to normal.</p><p>&nbsp;</p><p><em>Patients with renal impairment</em></p><p>The pharmacokinetics of cyproterone acetate in patients with renal impairment has not been investigated.</p><p>&nbsp;</p><p><u>Method of administration</u></p><p style="margin-left:0in; margin-right:0in; text-align:left">Oral use</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Contraindications">4.3 Contraindications</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                The following contraindications shall apply when indicated for ‘sex-drive suppression in the event of hypersexuality and sexual deviations’ in men
-	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1,
-	liver diseases,
-	Dubin-Johnson syndrome, Rotor syndrome,
-	presence or history of liver tumours,
-	known or suspected malignant diseases,
-	presence or history of meningiomas,
-	severe chronic depression,
-	history or presence of thromboembolic events,
-	severe diabetes mellitus with vascular changes,
-	sickle cell disease,
-	adolescents before the end of puberty and children (see section 4.2).

The following contraindications shall apply when indicated for ‘palliative treatment of advanced prostate carcinoma’ in men
-	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1,
-	liver diseases,
-	Dubin-Johnson syndrome, Rotor syndrome,
-	existing or history of liver tumours (only if they have not been caused by metastases of the prostate carcinoma),
-	known or suspected malignant diseases (other than advanced prostate carcinoma),
-	presence or history of meningiomas,
-	severe chronic depression,
-	presence of thromboembolic events,
-	adolescents before the end of puberty and children (see section 4.2).

The following contraindications shall apply when indicated for ‘severe to very severe signs of androgenisation’ (see section 4.1) in women
-	Hypersensitivity to the active substance or to any of the excipients listed in section 6.1,
-	during pregnancy,
-	whilst breastfeeding,
-	diagnostically inconclusive vaginal bleeding,
-	liver diseases,
-	Dubin-Johnson syndrome, Rotor syndrome,
-	idiopathic pregnancy or severe pruritus during pregnancy or respectively Pemphigoid gestationis in the medical history,
-	history or presence of liver tumours,
-	known or suspected malignant diseases,
-	presence or history of meningiomas,
-	severe chronic depression,
-	history or presence of thromboembolic events,
-	severe diabetes mellitus with vascular changes.
-	sickle cell disease,
-	adolescents before the end of puberty and children (see section 4.2).

Additionally, the information concerning contraindications and reasons to discontinue the oestrogen or progestogen-oestrogen combination immediately, which is contained in the respective package leaflets and summary of product characteristics, have to be followed when treating severe signs of androgenisation with combination therapy.

            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialWarnings">4.4. Special warnings and precautions for use</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>In patients with advanced prostate carcinoma, the benefits have to be weighed carefully against the risks of using this product on an individual basis, if thromboembolic processes, severe Diabetes mellitus with vascular changes or sickle-cell disease have been diagnosed in the past.</p><p>&nbsp;</p><p><u>Thromboembolic events (men and women)</u></p><p>The occurrence of thromboembolic events has been reported in patients using Androcur 50&nbsp;mg. Patients with previous arterial or venous thrombotic/thromboembolic events (e.g. deep vein thrombosis, pulmonary embolism, myocardial infarction), with a history of cerebrovascular accidents or with advanced malignant diseases are at increased risk of further thromboembolic events.</p><p>&nbsp;</p><p><u>Adrenal cortex (men and women)</u></p><p>The adrenocortical function should be checked regularly during treatment, since preclinical results indicate suppression due to the corticoid-like effect of Androcur 50&nbsp;mg (see section&nbsp;5.3).</p><p>&nbsp;</p><p><u>Liver (men and women)</u></p><p>Direct hepatotoxic reactions, such as jaundice, hepatitis and liver failure have been reported in patients treated with Androcur. Cases with fatal outcome have also been reported at doses of 100&nbsp;mg and more. Most of the reported fatalities were men with advanced prostate carcinoma. Toxicity is dose dependent and generally develops several months after the start of treatment.</p><p>Liver function should be checked prior to the start of treatment, at regular intervals during treatment, as well as whenever symptoms or signs suggest hepatotoxicity. As a rule, Androcur should be discontinued (men and women), if the suspicion of hepatotoxicity has been confirmed, the exception being, that the hepatotoxicity can be explained by another cause, such as metastases (in men). In this case, treatment with Androcur should only be continued, if the expected benefit outweighs the risk.</p><p>&nbsp;</p><p>Benign and malignant liver tumours (in very rare cases in men), which may lead to life-threatening intra-abdominal haemorrhage, have been observed as a result of using Androcur 50&nbsp;mg. A liver tumour should be considered in the differential diagnosis when severe upper abdominal complaints, liver enlargement or signs of intra-abdominal haemorrhage occur. If necessary, therapy should be discontinued.</p><p>&nbsp;</p><p><u>Meningioma (men and women):</u></p><p>In connection with the use of cyproterone acetate the occurrence of meningiomas (single and multiple) has been reported mainly at doses of 25&nbsp;mg per day and above. The risk of meningioma increases with increasing cumulative doses of cyproterone acetate (see section&nbsp;5.1). High cumulative doses can be attained by long-term use (several years) or in cases of shorter duration with high daily doses. Patients should be monitored for meningioma in accordance with clinical practice.</p><p>If a patient treated with Androcur 50&nbsp;mg is diagnosed with meningioma, treatment with Androcur 50&nbsp;mg and other medicinal products containing cyproterone acetate must be permanently discontinued (see section&nbsp;&rdquo;Contraindications&rdquo;).</p><p>There is some evidence to indicate that the risk for meningioma may reduce following cessation of treatment with cyproterone acetate.</p><p>&nbsp;</p><p><u>Carbohydrate metabolism (men and women)</u></p><p>There have been reports of increased blood sugar levels in diabetics treated with Androcur 50&nbsp;mg. Carbohydrate metabolism should be monitored carefully in patients with Diabetes mellitus before and regularly during treatment with Androcur 50&nbsp;mg since the required dose of oral antidiabetic drugs or insulin can change. See also section&nbsp;4.3.</p><p>&nbsp;</p><p><u>Breathing (men and women)</u></p><p>The feeling of being short of breath may occur during high-dosed administration of Androcur (common in men). In the differential diagnosis of such cases, the stimulatory effect of progesterone and synthetic progestogens on breathing should be considered, which is accompanied by hypocapnea and compensatory alkalosis, and which is not considered to require treatment.</p><p>&nbsp;</p><p><u>Erythropoiesis (men)</u></p><p>Cases of anaemia have occurred during treatment with Androcur 50&nbsp;mg. Therefore, the erythrocyte count in men has to be monitored regularly during treatment.</p><p>&nbsp;</p><p><u>Other conditions (men)</u></p><p>When using Androcur 50&nbsp;mg to suppress the sexual drive in hypersexuality and sexual deviations, the simultaneous use of alcohol makes it possible to diminish the libido-suppressing effect, due to its disinhibitory effect.</p><p>&nbsp;</p><p><u>Reproductive system and changes in the breast (men)</u></p><p>In the course of treatment for several weeks, spermatogenesis is often inhibited due to the anti-androgenic and anti-gonadotropic effect of cyproterone acetate. Likewise, the volume of ejaculate is reduced. The inhibition of spermatogenesis, which slowly develops during treatment, and which is generally associated with infertility, is reversible following discontinuation. Within a few months, sometimes up to 20&nbsp;months after ending therapy, spermatogenesis gradually normalises itself, reverting to its previous state prior to using Androcur. Even the effect on the ejaculate is completely reversible. Libido impairment and erectile dysfunction are very common. It is advisable in men of reproductive age, for whom fertility could be important once medication has been completed, to have at least one spermiogram check carried out prior to treatment as a precautionary measure. This can be used best to respond to any unfounded allegations about subsequent infertility being a result of anti-androgen therapy.</p><p>Gynaecomastia is common in treated men, which usually regresses after discontinuation of treatment or reduction of dosage.</p><p>&nbsp;</p><p><u>Adverse effects (women)</u></p><p>Pain, tension or enlargement of the breasts commonly occurs at the start of treatment. Loss of libido can occasionally be observed. Irregular gynaecological bleeding and amenorrhoea are very common.</p><p>&nbsp;</p><p>Hepatotoxic reactions (hepatitis, liver failure) are very rare. Little is known about the hepatotoxic mechanism of cyproterone acetate. Possibly, it is a direct hepatotoxic effect of the medicinal product; it is more probably caused, however, by a hypersensitivity reaction to a metabolite of cyproterone acetate.</p><p>&nbsp;</p><p>Presently available data indicate that the undesirable effects of cyproterone acetate occur more commonly in elderly patients, who are being treated with high doses over an extended period due to malignant diseases. For this reason, liver-function monitoring is absolutely necessary in these patients. Treatment with cyproterone acetate has to be discontinued, should pathological liver function values appear.</p><p>&nbsp;</p><p><u>Additional instructions for use (women)</u></p><p>Before starting treatment, a thorough gynaecological examination (including an examination of the breasts and a cytological cervical smear) must be conducted following the differential diagnosis of androgenisation signs and symptoms. Pregnancy has to be ruled out in the sexually mature due to the risk of feminising male foetuses.</p><p>&nbsp;</p><p>Combination treatment results in infertility because of the ovulation-inhibiting effect. After discontinuation, the menstrual cycle readjusts to its previous rhythm.</p><p>Treatment has to be stopped immediately if pregnancy does occur during combined therapy through compliance errors, medicinal product interactions, etc. The absence of a withdrawal bleed during the seven-day break may be an indication of pregnancy. Therefore, combination treatment may only be resumed when it is certain that there is no pregnancy.</p><p>&nbsp;</p><p>Tablet-taking should not be interrupted should irregular bleeding occur during the three-week combined treatment. However, if bleeding is persistent or recurrent at irregular intervals, a gynaecological examination is required to exclude organic disease.</p><p>&nbsp;</p><p>Additionally with regard to combination treatment, special references have to be followed, which are contained in the respective package leaflets and summary of product characteristics of the oestrogen or progestogen-oestrogen combination used.</p><p>&nbsp;</p><p><u>Treatment of hypersexuality and sexual deviations (men)</u></p><p>Sexual deviations are in need of treatment if psychological strain is present. The patient&#39;s request is required for treatment.</p><p>Given that sexual and androgenic activities are not necessary analogous, suppression of the androgenic activity will not always be accompanied by a suppression of the sexual drive.</p><p>&nbsp;</p><p>As a matter of principle, psychiatric, psychotherapeutic and socio-therapeutic measures will be necessary. Suppressing sexuality through treatment with cyproterone-acetate tablets can be advantageous, when these measures are adopted.</p><p>&nbsp;</p><p>Patients with organic brain damage or a mental disorder, who suffer from deviant sexual behaviour, are usually therapy-resistant.</p><p>&nbsp;</p><p>In the event of possible fertility disorders, it is advisable to have a spermiogram done before starting treatment.</p><p>&nbsp;</p><p><u>Lactose warning (men and women)</u></p><p>Patients with the rare hereditary galactose intolerance, lactase deficiency or glucose-galactose malabsorption should not take Androcur 50&nbsp;mg.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="InteractionsOtherMedicines">4.5. Interactions with other medicinal products</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Although clinical interaction studies have not been performed, it is expected that ketoconazole, itraconazole, clotrimazole, ritonavir and other strong inhibitors of CYP3A4 inhibit the metabolism of cyproterone acetate, since this medicinal product is metabolised by CYP3A4. On the other hand, inducers of CYP3A4 such as rifampicin, phenytoin, and products containing St. John&#39;s wort may reduce the level of cyproterone acetate.</p><p><em>In‑vitro</em> inhibition studies confirm a potential inhibition of the cytochrome P450 enzymes, CYP2C8, 2C9, 2C19, 3A4 and 2D6, at high therapeutic doses of 100&nbsp;mg cyproterone acetate three times per day.</p><p>&nbsp;</p><p>The risk of statin-related myopathy or rhabdomyolysis may be increased, when such HMG‑CoA inhibitors (statins), which are primarily metabolised by CYP3A4, are co-administered with high therapeutic doses of cyproterone acetate, since they are subject to the same metabolic pathway.</p><p>&nbsp;</p><p>Additionally, the information concerning interactions, which is contained in the respective package leaflets and summary of product characteristics of the oestrogen or progestogen-oestrogen combination used, have to be followed when treating severe signs of androgenisation with combination therapy.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="FertilityAndPregnantWarnings">4.6. Fertility, pregnancy and lactation</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>The use of Androcur 50&nbsp;mg is contraindicated during pregnancy and lactation (see section&nbsp;4.3).</p><p>&nbsp;</p><p><u>Pregnancy</u></p><p>Administration of CPA during the hormone-sensitive differentiation phase of the genital organs caused signs of feminisation in male foetuses following high doses in animal studies. Animal studies on embryo-toxicity revealed no evidence of teratogenicity.</p><p>&nbsp;</p><p>Based on 100,000&nbsp;woman-years of CPA exposure, there were 0.2&nbsp;cases reported, in which male foetuses were exposed in utero to CPA. In the majority of these cases, the women involved had taken 2&nbsp;mg CPA per day during the first trimester of pregnancy. In isolated cases, 100&nbsp;mg CPA were taken per day up to the second trimester or respectively 2&nbsp;mg CPA per day up to the third trimester of pregnancy. None of the male neonates in these cases showed any signs of feminisation. Nonetheless, gravidity is a contraindication for the use of Androcur 50&nbsp;mg.</p><p>&nbsp;</p><p>&nbsp;</p><p><u>Breastfeeding</u></p><p>CPA passes into breast milk. About 0.2% of the maternal dose can be transferred to the nursing infant.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="EffectsAbilityDriveMachines">4.7. Effects on ability to drive and use machines</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Androcur 50&nbsp;mg can cause fatigue and decreased vitality and may impair the ability to concentrate. Androcur 50&nbsp;mg can, even under normal conditions of use, alter the ability to react to such an extent, that the ability to participate actively in traffic and to operate machinery is impaired.</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="UndesirableEffects">4.8. Undesirable effects</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Men</u></p><p>The most commonly reported adverse drug reactions, (ADRs) in male patients taking Androcur 50&nbsp;mg are decreased libido, erectile dysfunction and reversible inhibition of spermatogenesis.</p><p>&nbsp;</p><p>The most serious adverse drug reactions involved hepatotoxic reactions, benign and malignant liver tumours, which may cause intra-abdominal haemorrhage, and thromboembolic events.</p><p>&nbsp;</p><p><u>Women</u></p><p>The most commonly reported adverse drug reactions, (ADRs) in female patients taking Androcur 50&nbsp;mg are breakthrough bleeding, weight gain and depressive mood.</p><p>The most serious adverse drug reactions involved hepatotoxic reactions, benign and malignant liver tumours, which may cause intra-abdominal haemorrhage, and thromboembolic events.</p><p>&nbsp;</p><p>The following table lists the adverse drug reactions, which have been reported in connection with Androcur 50&nbsp;mg. Adverse drug reactions, which were only reported as post-marketing data and for which frequency cannot be estimated, are listed under the frequency category, &lsquo;frequency not known&rsquo;.</p><p>&nbsp;</p><p>The following categories are used to rank adverse drug reactions by frequency of occurrence</p><p>Very common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;&nbsp;1/10)<br />Common &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;&nbsp;1/100 to &lt;&nbsp;1/10)<br />Uncommon &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;&nbsp;1/1,000 to &lt;&nbsp;1/100)<br />Rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&ge;&nbsp;1/10,000 to &lt;&nbsp;1/1,000)<br />Very rare &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (&lt;&nbsp;1/10,000)<br />Not known &nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; (frequency cannot be estimated from the available data)</p><p>&nbsp;</p><p>The most appropriate MedDRA term has been used to describe a particular reaction. Synonyms and related conditions are not listed but should also be considered.</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1" style="width:646px"><tbody><tr><td style="vertical-align:top; width:83.4pt"><p><strong>System Organ Class, MedDRA</strong></p></td><td style="vertical-align:top; width:71.9pt"><p><strong>Very common</strong></p></td><td style="vertical-align:top; width:60.1pt"><p><strong>Common</strong></p></td><td style="vertical-align:top; width:70.9pt"><p><strong>Uncommon</strong></p></td><td style="vertical-align:top; width:63.8pt"><p><strong>Rare</strong></p></td><td style="vertical-align:top; width:63.75pt"><p><strong>Very rare</strong></p></td><td style="vertical-align:top; width:70.9pt"><p><strong>Frequency not known</strong></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Neoplasms Benign, Malignant and Unspecified (incl. cysts and polyps)</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Meningioma</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Benign and malignant liver tumours <em>(men)</em>*</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Benign and malignant liver tumours <em>(women)*</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Investigations</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Prolactin levels slightly increased</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Decreased cortisol levels</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Blood and lymphatic system disorders</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Anaemia <em>(men)*</em></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Respiratory, thoracic and mediastinal disorders</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Shortness of breath <em>(men)*</em></p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Shortness of breath <em>(women)*</em></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Skin and subcutaneous tissue disorders</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Rash <em>(men)</em></p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Rash <em>(women)</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Dry skin</p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Musculoskeletal, connective tissue and bone disorders</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Osteoporoses <em>(men)</em></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Metabolism and nutrition disorders</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Weight gain or weight loss <em>(men)</em></p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Weight gain <em>(women)</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Weight loss <em>(women)</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Rise in blood sugar in diabetics <em>(men and women)*</em></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Vascular disorders</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Thromboembolic events <em>(men and women</em>)*</p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">General disorders and administration site conditions</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p>Fatigue <em>(men)</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Hot flushes <em>(men)</em>, Sweating <em>(men)</em></p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p>Fatigue <em>(women)</em></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Immune system disorders</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Hypersensitivity reactions <em>(men)</em></p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Hypersensitivity reactions <em>(women)</em></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Hepatobiliary disorders</p></td><td style="vertical-align:top; width:71.9pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p>Hepatotoxic reactions, such as jaundice, hepatitis, liver failure <em>(men)*</em></p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Hepatotoxic reactions, such as jaundice, hepatitis, liver failure <em>(women)*</em></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Reproductive system and breast disorders</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Reversible inhibition of spermatogenesis <em>(men)</em></p></td><td style="vertical-align:top; width:60.1pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Gynaecomastia <em>(men)</em></p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Tenderness to touch of the mamillae<br /><em>(men)</em></p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p>Inhibition of ovulation <em>(women)</em></p><p>Pain and tension in the breast (women)</p><p>Enlargement of the breasts <em>(women)</em></p><p>Spotting <em>(women)</em>*</p><p>Irregular gynaecological bleeding (women)</p><p>Amenorrhea <em>(women)</em></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p>Psychiatric disorders</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Decreased libido <em>(men)</em></p><p style="margin-left:0in; margin-right:0in; text-align:left">Erectile dysfunction <em>(men)</em></p></td><td style="vertical-align:top; width:60.1pt"><p>Depressive moods <em>(men)</em></p><p>Transient restlessness <em>(men)</em></p><p>Lassitude</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p>Depressive moods <em>(women)</em></p><p>Transient restlessness <em>(women)</em></p><p>Decreased libido <em>(women)</em></p><p>Increased libido <em>(women)</em></p></td></tr><tr><td style="vertical-align:top; width:83.4pt"><p style="margin-left:0in; margin-right:0in; text-align:left">Gastrointestinal disorders</p></td><td style="vertical-align:top; width:71.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:60.1pt"><p>&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.8pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:63.75pt"><p style="margin-left:0in; margin-right:0in; text-align:left">&nbsp;</p></td><td style="vertical-align:top; width:70.9pt"><p>Intra-abdominal haemorrhage <em>(men and women)*</em></p></td></tr></tbody></table><p style="margin-left:0in; margin-right:0in"><sup>&sect;</sup>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; See section&nbsp;4.3</p><p>*&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; For further information see <strong>s</strong>ection<strong>&nbsp;</strong>4.4</p><p>&nbsp;</p><p>Stomach complaints, dizziness, headache and nausea have been commonly reported primarily in women in connection with medicinal products, which contain cyproterone acetate as their active ingredient.</p><p>&nbsp;</p><p>The occurrence of meningiomas (single and multiple) has been reported in connection with the use of cyproterone acetate (see section&nbsp;4.4).</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">Isolated cases of anaemia and a reduction in endogenous cortisol production were observed with high-dose treatment with cyproterone acetate (see section&nbsp;4.4).</p><p><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in">Treatment with Androcur diminished sexual drive and potency, and inhibited gonadal function in male patients. These changes are reversible after discontinuing treatment.</p><p><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in">Spermatogenesis is inhibited as a result of the anti-androgenic and anti-gonadotropic effect in men during the course of several weeks of treatment. Spermatogenesis gradually re-establishes itself within a few months after discontinuation of therapy (see section&nbsp;4.4).</p><p><strong>&nbsp;</strong></p><p style="margin-left:0in; margin-right:0in">Gynaecomastia is common in treated men. It is uncommonly associated with the nipples being more sensitive to touch. These changes mostly revert to their previous state after the end of treatment.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">As is the case with other anti-androgenic active substances, the long-term use of Androcur can also, in very rare cases, cause osteoporosis in men.</p><p><strong>&nbsp;</strong></p><p>The ovarian function is inhibited in women during combined treatment with a suitable oestrogen or a suitable progestogen-oestrogen combination with the intention that infertility will continue throughout treatment.</p><p>&nbsp;</p><p style="margin-left:0in; margin-right:0in">With regard to the necessary combination treatment in women, the special references to adverse drug reactions have to be followed, which are contained in the respective package leaflets and summary of product characteristics of the oestrogen or progestogen-oestrogen combination used.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">Androcur causes a negative nitrogen balance at the start of treatment, which, however, equalises itself during the course of use. As a precautionary measure due to this initial catabolic effect, Androcur 50&nbsp;mg should not be given if there are known or suspected malignant diseases (exception: prostate carcinoma) (see section&nbsp;4.3).</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">A tendency toward a slight increase in prolactin levels was occasionally observed at high doses of CPA.</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="margin-left:0in; margin-right:0in">Dry skin can occur due to decreased secretion of the sebaceous glands.</p><p>&nbsp;</p><p><u>Reporting of suspected adverse reactions</u></p><p>Reporting suspected adverse reactions after authorisation of the medicinal product is important. It allows continued monitoring of the benefit/risk balance of the medicinal product. Healthcare professionals are asked to report any suspected adverse reactions via:</p><p style="margin-left:0in; margin-right:0in">&nbsp;</p><p style="text-align:left"><strong>To report any side effect(s):</strong></p><p style="text-align:left">The National Pharmacovigilance Centre (NPC).</p><p style="text-align:left">SFDA Call Center: 19999</p><p style="text-align:left">E-mail: npc.drug@sfda.gov.sa</p><p style="text-align:left">Website: https://ade.sfda.gov.sa</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Overdoes">4.9. Overdoes</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>There are no indications pointing toward serious adverse health effects resulting from an overdose of Androcur 50&nbsp;mg. Studies on acute toxicity after single-dose administration have shown, that cyproterone acetate, the active component of Androcur 50&nbsp;mg, has to be classified as virtually non-toxic. Similarly, acute intoxication is not to be expected following a single accidental ingestion of multiple treatment doses.</p>
            </div>
        </div>
    </div>

    <div class="col-xs-12">
        <label style="float: left">5. PHARMACOLOGICAL PROPERTIES</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PharmacodynamicProperties">5.1. Pharmacodynamic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Pharmacotherapeutic group: Anti-androgen, pure, cyproterone; ATC&nbsp;Code: G03&nbsp;HA01</p><p>&nbsp;</p><p>CPA has an anti-androgen, a progestogenic, and an anti-gonadotropic effect. These three partial effects are identifiable in animals and humans.</p><p>&nbsp;</p><p><u>Endocrine pharmacological investigations in animals</u></p><p><strong>&nbsp;</strong></p><p><em>Anti-androgenic effect</em></p><p>CPA prevents the effect of endogenous and exogenous androgens on the target organs by competitive inhibition. This blocks the translocation of the DHT-receptor complex into the nucleus. <em>In‑vitro</em> cell-culture experiments, testing the effect of CPA on the androgen receptor functions, show CPA to have a high anti-androgenic potency. Additionally, in some <em>in‑vitro</em> test systems, there is a slight partial agonist effect of CPA at the androgen receptor. The stimulatory effect of male sex hormones on androgen-dependent structures and functions is weakened or cancelled by CPA: In animals CPA leads to dose-dependent atrophy of the accessory sex glands, i.e., prostate, seminal vesicles and preputial glands. It affects testicular function: Spermatogenesis is inhibited dose-dependently. Similarly in humans, CPA inhibits the libido in dogs, rabbits, pigs and monkeys.</p><p>In rats, the onset of puberty can be prevented or delayed. CPA inhibits the physiological epiphyseal plate closure and bone maturation.</p><p>It affects the sebaceous gland function; the thickness of the epidermis decreases.</p><p>Treating pregnant animals with CPA results in developmental disorders in male foetuses. Testosterone-dependent differentiation processes are affected: there are more or less prominent signs of feminisation as a result.</p><p>&nbsp;</p><p><em>Progestogenic effect</em></p><p>The Clauberg test (in rabbits) proved the potency of CPA to be 100-fold greater following subcutaneous administration than that of progesterone. In testing for progestogenic effects in rats, CPA is about as potent as progesterone following subcutaneous administration.</p><p>&nbsp;</p><p><em>Anti-gonadotropic effect</em></p><p>As do all potent progestogens, CPA has anti-gonadotropic properties, which manifest themselves in males by inhibiting testicular growth and in females by inhibiting ovulation.</p><p>&nbsp;</p><p><u>Endocrine pharmacological investigations in humans</u></p><p><u>&nbsp;</u></p><p><em>Anti-androgenic effect</em></p><p>CPA inhibits competitively the effect of androgens at their target organs. The following associated effects, among others, have been described in humans: inhibition of sexual drive, reduction of sebaceous gland activity, influence on hair growth, prevention of androgenic growth impulses to the prostatic tissue, inhibition of premature adolescent developmental processes, including bone.</p><p>&nbsp;</p><p><em>Progestogenic effect</em></p><p>CPA is a potent progestogen. According to the Kaufmann assay, it causes endometrial transformation from a total dose of 20 to 30&nbsp;mg.</p><p>&nbsp;</p><p><em>Anti-gonadotropic effect</em></p><p>As a potent progestogen, CPA has a central inhibitory effect. On account of this anti-gonadotropic effect there is no counter-regulatory increase in LH secretion, although androgens are blocked by the anti-androgenic effect of CPA also at the receptors in the hypothalamus, at which they exert their negative feedback.</p><p>Rather, the LH secretion and that of the FSH are inhibited by the progestogenic partial effect of CPA. As a result, there is a decrease of testosterone and oestrogens in plasma.</p><p>This central inhibitory effect of CPA also comes into play in combination with LHRH-agonists. The initial increase in testosterone, caused by this group of substances, is diminished by CPA.</p><p><strong>&nbsp;</strong></p><p><em>Further effects on endocrine parameters</em></p><p>CPA causes the concentration of testosterone and estrogens to decline.</p><p>No significant influence on 17‑ketosteroids and 17‑ketogenic steroids has been found. Cortisol secretion remained unchanged or decreased. The function of the hypothalamic-pituitary-adrenal axis (HPA axis) was largely unaffected in adults. The evaluation of all results suggests that the reactivity of the system is usually not affected.</p><p>&nbsp;</p><p><em>Meningioma</em></p><p>Based on a French epidemiological cohort study, a cumulative dose-dependent relationship was observed between cyproterone acetate and meningiomas. This study was based on data from the French health insurance (CNAM) and included a population of 253,777 women, who were taking tablets of 50-100&nbsp;mg cyproterone acetate. The incidence of meningioma treated by surgery or radiation therapy was compared between women exposed to high-dose cyproterone acetate (cumulative dose &sup3;&nbsp;3g) and women with only low exposure to cyproterone acetate (cumulative dose &lt;&nbsp;3&nbsp;g). A correlation was revealed between the cumulative dose and occurrence.</p><p>&nbsp;</p><table cellspacing="0" cellpadding="0" border="1"><tbody><tr><td style="vertical-align:top; width:137.1pt"><p>Cumulative dose of cyproterone acetate</p><p>&nbsp;</p></td><td style="vertical-align:top; width:140.15pt"><p>Incidence rate (in patient years)</p></td><td style="vertical-align:top; width:127.05pt"><p>HR<sub>adj</sub> (95% CI)<sup>a</sup></p></td></tr><tr><td style="vertical-align:top; width:137.1pt"><p>Mild exposure (&lt;&nbsp;3&nbsp;g)</p></td><td style="vertical-align:top; width:140.15pt"><p>4.5/100,000</p></td><td style="vertical-align:top; width:127.05pt"><p>Ref.</p></td></tr><tr><td style="vertical-align:top; width:137.1pt"><p>Exposure up to &sup3;&nbsp;3&nbsp;g</p></td><td style="vertical-align:top; width:140.15pt"><p>23.8/100,000</p></td><td style="vertical-align:top; width:127.05pt"><p>6.6 [4.0-11.1]</p></td></tr><tr><td style="vertical-align:top; width:137.1pt"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 12 to 36&nbsp;g</p></td><td style="vertical-align:top; width:140.15pt"><p>26/100,000</p></td><td style="vertical-align:top; width:127.05pt"><p>6.4 [3.6-11.5]</p></td></tr><tr><td style="vertical-align:top; width:137.1pt"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; 36 to 60&nbsp;g</p></td><td style="vertical-align:top; width:140.15pt"><p>54.4/100,000</p></td><td style="vertical-align:top; width:127.05pt"><p>11.3 [5.8-22.2]</p></td></tr><tr><td style="vertical-align:top; width:137.1pt"><p>&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp;&nbsp; more than 60&nbsp;g</p></td><td style="vertical-align:top; width:140.15pt"><p>129.1/100,000</p></td><td style="vertical-align:top; width:127.05pt"><p>21.7 [10.8-43.5]</p></td></tr></tbody></table><p>*Adjusted according to age as a time-dependent variable and oestrogen at start of application</p><p style="margin-left:60.1pt; margin-right:0in">&nbsp;</p><p>A cumulative dose of, for example, 12&nbsp;g may correspond to one year of treatment with 50&nbsp;mg/day for 20&nbsp;days per month</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
                <label style="float: left" for="PharmacokineticProperties">5.2. Pharmacokinetic Properties</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Systemic toxicity</u></p><p>Preclinical data reveal no specific hazard for humans based on conventional studies on chronic toxicity.</p><p><u>&nbsp;</u></p><p><u>Toxicity to reproduction</u></p><p>The temporary inhibition of fertility in male rats, as a result of daily oral treatment, revealed no evidence that germ cells are damaged in ways that could lead to maldevelopment or fertility disorders in the offspring.</p><p><u>&nbsp;</u></p><p><u>Genotoxicity/carcinogenicity</u></p><p>Recognised first-line tests of genotoxicity gave no indication of a mutagenic effect when conducted with CPA. However, further tests showed that CPA was capable of producing adducts with DNA (and an increase in DNA repair activity) in liver cells from rats, monkeys and humans. This DNA-adduct formation occurred at systemic exposures that might be expected to occur in the recommended dose regimen. One consequence of <em>in‑vivo</em> cyproterone acetate treatment was the increased incidence of focal, possibly pre-neoplastic, liver lesions in which cellular enzymes were altered in female rats and an increased mutation frequency in transgenic rats, carrying a bacterial gene as a mutation marker.</p><p>The clinical significance of these findings is currently uncertain. Clinical experience to date and carefully conducted epidemiological studies do not support an increased incidence of hepatic tumours in humans.</p><p>Investigations into the tumourigenicity of CPA in rodents did not reveal any results that fundamentally differed from those obtained with other steroid hormones. It must be borne in mind, however, that sex steroids can promote the growth of certain hormone-dependent tissue and tumours.</p><p>Overall, there is nothing in the available data to contradict the use of Androcur 50&nbsp;mg in humans, if this use is in accordance with labelled indications and the recommended dosage.</p><p>In experimental studies in rats and dogs, high doses caused corticoid-like effects on the adrenal glands, which could point to similar effects in humans at the highest dose (300&nbsp;mg/day).</p><p>&nbsp;</p><p>&nbsp;</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PreclinicalSafetyData">5.3 Preclinical Safety Data</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p><u>Systemic toxicity</u></p><p>Preclinical data reveal no specific hazard for humans based on conventional studies on chronic toxicity.</p><p><u>&nbsp;</u></p><p><u>Toxicity to reproduction</u></p><p>The temporary inhibition of fertility in male rats, as a result of daily oral treatment, revealed no evidence that germ cells are damaged in ways that could lead to maldevelopment or fertility disorders in the offspring.</p><p><u>&nbsp;</u></p><p><u>Genotoxicity/carcinogenicity</u></p><p>Recognised first-line tests of genotoxicity gave no indication of a mutagenic effect when conducted with CPA. However, further tests showed that CPA was capable of producing adducts with DNA (and an increase in DNA repair activity) in liver cells from rats, monkeys and humans. This DNA-adduct formation occurred at systemic exposures that might be expected to occur in the recommended dose regimen. One consequence of <em>in‑vivo</em> cyproterone acetate treatment was the increased incidence of focal, possibly pre-neoplastic, liver lesions in which cellular enzymes were altered in female rats and an increased mutation frequency in transgenic rats, carrying a bacterial gene as a mutation marker.</p><p>The clinical significance of these findings is currently uncertain. Clinical experience to date and carefully conducted epidemiological studies do not support an increased incidence of hepatic tumours in humans.</p><p>Investigations into the tumourigenicity of CPA in rodents did not reveal any results that fundamentally differed from those obtained with other steroid hormones. It must be borne in mind, however, that sex steroids can promote the growth of certain hormone-dependent tissue and tumours.</p><p>Overall, there is nothing in the available data to contradict the use of Androcur 50&nbsp;mg in humans, if this use is in accordance with labelled indications and the recommended dosage.</p><p>In experimental studies in rats and dogs, high doses caused corticoid-like effects on the adrenal glands, which could point to similar effects in humans at the highest dose (300&nbsp;mg/day).</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <label style="float: left">6. PHARMACEUTICAL PARTICULARS</label>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ExcipientsList">6.1 Excipients List</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Lactose monohydrate</p><p>Maize starch</p><p>Povidone&nbsp;K25</p><p>Colloidal anhydrous silica</p><p>Magnesium stearate (Ph.&nbsp;Eur.)</p><p><strong>&nbsp;</strong></p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="Incompatibilities">6.2. Incompatibilities</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Not applicable.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ShelfLife">6.3. Shelf Life</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                4 years
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="PrecautionsStorageConditions">6.4. Special precautions for storage</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Store below 25&deg;C.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="ContainerContents">6.5. Nature and contents of container</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>Blister packs made of polyvinyl chloride and hardened aluminium.</p><p>&nbsp;</p><p>Pack with 20&nbsp;tablets</p><p>Pack with 50&nbsp;tablets</p><p>Pack with 100&nbsp;tablets</p><p>Hospital packs with 250&nbsp;tablets</p><p>&nbsp;</p><p>Not all pack sizes may be marketed</p>
            </div>
        </div>
    </div>
    <div class="col-xs-11 col-offset">
        <div class="clearfix">
            <label style="float: left" for="SpecialPrecautionsDisposal">6.6. Special precautions for disposal and other handling</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                <p>No special requirements.</p>
            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="AuthorizationMarketingHolder">7. MARKETING AUTHORISATION HOLDER</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                Bayer AG,
51368 Leverkusen
Germany.


            </div>
        </div>
    </div>
    <div class="col-xs-12">
        <div class="clearfix">
            <label style="float: left" for="RevisionDateText">8. DATE OF REVISION OF THE TEXT</label>
        </div>
        <div class="form-group">
            <br />
            <div class="ltr">
                April 2020
            </div>
        </div>
    </div>
</div>

            }    </div>
    <div id="f-div" class="box-data">
        
<div class="row clearfix rtl">
    <div class="container-fluid">
        <!-- Basic Example -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>صورة المنتج على الرف</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic" data-slide-to="0" class="active"></li>
                        <li data-target="#carousel-example-generic" data-slide-to="1" class=""></li>
                        <li data-target="#carousel-example-generic" data-slide-to="2" class=""></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                            
                                <img src="/images/nodrugimags.png">
                        </div>

                    </div>

                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# Basic Example -->
        <!-- With Captions -->
        <div class="col-lg-6 col-md-6 col-sm-6 col-xs-6">
            <div class="header">
                <h2>الصورة الاساسية</h2>
            </div>
            <div class="body">
                <div id="carousel-example-generic_2" class="carousel slide" data-ride="carousel">
                    <!-- Indicators -->
                    <ol class="carousel-indicators">
                        <li data-target="#carousel-example-generic_2" data-slide-to="0" class=""></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="1" class="active"></li>
                        <li data-target="#carousel-example-generic_2" data-slide-to="2"></li>
                    </ol>
                    <!-- Wrapper for slides -->
                    <div class="carousel-inner" role="listbox">
                        <div class="item active">
                                <img src="/images/nodrugimags.png">
                        </div>
                    </div>
                    <!-- Controls -->
                    <a class="left carousel-control" href="#carousel-example-generic_2" role="button" data-slide="prev">
                        <span class="glyphicon glyphicon-chevron-right" aria-hidden="true"></span>
                        <span class="sr-only">Previous</span>
                    </a>
                    <a class="right carousel-control" href="#carousel-example-generic_2" role="button" data-slide="next">
                        <span class="glyphicon glyphicon-chevron-left" aria-hidden="true"></span>
                        <span class="sr-only">Next</span>
                    </a>
                </div>
            </div>
        </div>
        <!-- #END# With Captions -->
    </div>
</div>


    </div>

    <!-- #END# Tabs With Custom Animations -->
</div>
        <a style="background-image: url('../images/banner.png');"
           class="scroll-top">
            <img style="margin: 15px;" src="/images/icons/up-arrow2.png" width="35">
        </a>

        <div class="footer navbar-fixed-bottom">
            <small style="color: white; margin-left: 30px;">All Rights Reserved - SFDA &copy; 2020</small>
            <br class="visible-xs visible-sm"><br class="visible-xs visible-sm">

        </div>
    </section>


    <script src="/lib/json2/json2.js?v=w3DjWhUtDqy3bSJKv285C-2kagUtW9F64T9z3xRah8g"></script>
    <script src="/lib/jquery/dist/jquery.js?v=w4hyv6-vmv08RC2hK00wXgxDziKII9paMAbU_M-5dgY"></script>
    <script src="/lib/bootstrap/dist/js/bootstrap.js?v=T574NvJTWc-Pan8hAmnXXc0eZFiqKRp7xQ3sz5QiFOk"></script>
    <script src="/lib/moment/min/moment-with-locales.js?v=5f0RFtuChrGi6osDzegxXWf5yOkmx45i7J9fM1p6P5w"></script>
    <script src="/lib/jquery-validation/dist/jquery.validate.js?v=ZDzsHzuLAtqQVxXwbgRtfAPXQ7UAoJRXBAUDvc9G9CI"></script>
    <script src="/lib/blockUI/jquery.blockUI.js?v=KKcUNqwNyTLaXzvuMyFk6JisiQq6Hk7ZtrciXnEf3Z0"></script>
    <script src="/lib/toastr/toastr.js?v=s1ewxfN8Vn23TAVRLUk8XiQUAw6uWhhuPO9dmtYzUiA"></script>
    <script src="/lib/sweetalert/dist/sweetalert.min.js?v=aPktydUv1rN3mouQeXoKi3ioFTIQlULuqYeoTAA2ihY"></script>
    <script src="/lib/spin.js/spin.js?v=b1plKpQIB-XuGyjWec42MhmhpPzEPzFI3OC8Ia0XIoc"></script>
    <script src="/lib/spin.js/jquery.spin.js?v=i7H7HL08ldqUANgfQInE7LlU2uWUdQMCJ-Q7-_zLutY"></script>
    <script src="/lib/bootstrap-select/dist/js/bootstrap-select.js?v=tXulJKckrq2j2wo8a9hvmXLDEQwhGviPTIYmEzy1dNI"></script>
    <script src="/lib/jquery-slimscroll/jquery.slimscroll.js?v=ESVSX4dkOxamaRoYfcqPM2FfErhgfxS60fp1Fa8ou1w"></script>
    <script src="/lib/Waves/dist/waves.js?v=ZOMv1vwqpT_ezNZGhvr9jJTr_jqu3lYHB7vmpxD7HmA"></script>
    <script src="/lib/push.js/push.js?v=w347yqiscLjM_TxUKpqeUA1LDR3w5vshQpxpTsgkLhE"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/abp.js?v=EjNSmvtPSqCVK_xG_aTvOp8hmVM_7vwyd3hg45CAMGk"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.jquery.js?v=XEXcdRYb4eN3XoQCbnM-BSR6UifHRLsXYDIVFZ7Oc6Q"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.toastr.js?v=h3viOCmHM1K7HnYUuJPDvLchk2Ge8CoKvl6ZJfICgII"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.blockUI.js?v=vMuHbqHh635SKL2RG2qsGGCDyHg1yFeGqhPKpS34g4k"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.spin.js?v=djoKib6ssm5DDzbXLe5pD7ayfFg3siaoEk-BFYzQlvI"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.sweet-alert.js?v=fPp3O_ILaqD0UHiR721w1i4iBtxo3NH7yfldI5dg0_I"></script>
    <script src="/js/admin.js?v=nakObLuf3yPs2VlWrIris5w-48c36X3YIRrxIis7IKQ"></script>
    <script src="/js/main.js?v=x_HDlXByl0okIi4i04d4Q_fNr85GPQi1W8gjs82s-n8"></script>
    <script src="/view-resources/Views/Shared/_Layout.js?v=36YkLzPJaGejZMB10f2T6f1rMVIzDKq96kjfcnxcLVg"></script>


        <script src="/lib/jquery-validation/src/localization/messages_ar.js?v=6kzy-p-PtvkHPWdHWyjMOIfwhBFlUYYv9jnF7zJnpUI"></script>

    <!-- Dynamic scripts of ABP system (They are created on runtime and can not be bundled) -->
    <script src="/AbpServiceProxies/GetAll?v=638865394571695575" type="text/javascript"></script>
    <script src="/AbpScripts/GetScripts?v=638865394571695575" type="text/javascript"></script>
    <script src="/lib/signalr-client/signalr.min.js?v=1yGr-J4NjYMQVt6LP6vocjHIWhO-BFQLfdCs8x1Mv-U"></script>
    <script src="/lib/abp-web-resources/Abp/Framework/scripts/libs/abp.signalr-client.js?v=jTdZBAadu6DXq0iDTFX6vsn4q6bFhKm3XfN8Jz6dSmg"></script>
    
    <!-- View specific scripts -->
    
    <script src="/view-resources/Views/Home/Index.js?v=mAIakROmG_IlahImCtfrMSdaLPTG5Uoh6Z0hM1g3cxw"></script>
    <script src="/view-resources/Views/Home/Result.js?v=0pEgOuTQc8ZyJaaOpJCG7ytkKSCkzEMYCHEJfKDWu4k"></script>
    <script src="/view-resources/Views/Home/DrugsSearch.js?v=04aRniTG_ClH5tABzf7EDwQgWVpkDNpjeJUDSGvOK_Y"></script>

</body>
</html>